WO2020044118A1 - Improved cannabinoid bioavailability - Google Patents
Improved cannabinoid bioavailability Download PDFInfo
- Publication number
- WO2020044118A1 WO2020044118A1 PCT/IB2019/000964 IB2019000964W WO2020044118A1 WO 2020044118 A1 WO2020044118 A1 WO 2020044118A1 IB 2019000964 W IB2019000964 W IB 2019000964W WO 2020044118 A1 WO2020044118 A1 WO 2020044118A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thc
- cbd
- cannabinoid
- formulation
- oil
- Prior art date
Links
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 303
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 302
- 239000000203 mixture Substances 0.000 claims abstract description 204
- 238000009472 formulation Methods 0.000 claims abstract description 174
- 229940065144 cannabinoids Drugs 0.000 claims abstract description 124
- 238000000034 method Methods 0.000 claims abstract description 93
- 229960004242 dronabinol Drugs 0.000 claims description 252
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 248
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 247
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 204
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 202
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 202
- 229950011318 cannabidiol Drugs 0.000 claims description 202
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 202
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 claims description 114
- 239000003921 oil Substances 0.000 claims description 106
- 235000019198 oils Nutrition 0.000 claims description 105
- 150000002632 lipids Chemical class 0.000 claims description 88
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 74
- 239000002775 capsule Substances 0.000 claims description 67
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 claims description 61
- 239000002199 base oil Substances 0.000 claims description 58
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 claims description 57
- -1 medium- chain fatty acids MCFAs Chemical class 0.000 claims description 50
- 239000003826 tablet Substances 0.000 claims description 49
- 235000016401 Camelina Nutrition 0.000 claims description 48
- 239000002702 enteric coating Substances 0.000 claims description 48
- 238000009505 enteric coating Methods 0.000 claims description 48
- 239000007908 nanoemulsion Substances 0.000 claims description 46
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 claims description 45
- 239000002245 particle Substances 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 239000000839 emulsion Substances 0.000 claims description 35
- 239000002552 dosage form Substances 0.000 claims description 28
- 208000002193 Pain Diseases 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 25
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 23
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims description 20
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 19
- 230000036407 pain Effects 0.000 claims description 19
- 210000004185 liver Anatomy 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 229940106134 krill oil Drugs 0.000 claims description 17
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 239000002207 metabolite Substances 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 150000003904 phospholipids Chemical class 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000006187 pill Substances 0.000 claims description 13
- 239000008159 sesame oil Substances 0.000 claims description 13
- 235000011803 sesame oil Nutrition 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 235000021323 fish oil Nutrition 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 9
- 230000036506 anxiety Effects 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 208000000094 Chronic Pain Diseases 0.000 claims description 8
- 208000001640 Fibromyalgia Diseases 0.000 claims description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 8
- 206010028813 Nausea Diseases 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 8
- 230000036626 alertness Effects 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 239000010408 film Substances 0.000 claims description 8
- 230000008693 nausea Effects 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 8
- 208000019116 sleep disease Diseases 0.000 claims description 8
- YOVRGSHRZRJTLZ-HZPDHXFCSA-N 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol Chemical compound C1=C(C(O)=O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YOVRGSHRZRJTLZ-HZPDHXFCSA-N 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 7
- 206010017533 Fungal infection Diseases 0.000 claims description 7
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 7
- 208000031888 Mycoses Diseases 0.000 claims description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 7
- 208000021017 Weight Gain Diseases 0.000 claims description 7
- 230000000454 anti-cipatory effect Effects 0.000 claims description 7
- 230000036528 appetite Effects 0.000 claims description 7
- 235000019789 appetite Nutrition 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 7
- 206010061428 decreased appetite Diseases 0.000 claims description 7
- 206010022437 insomnia Diseases 0.000 claims description 7
- 235000011475 lollipops Nutrition 0.000 claims description 7
- 239000007937 lozenge Substances 0.000 claims description 7
- 230000003880 negative regulation of appetite Effects 0.000 claims description 7
- 230000009826 neoplastic cell growth Effects 0.000 claims description 7
- 230000003349 osteoarthritic effect Effects 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 208000018198 spasticity Diseases 0.000 claims description 7
- 230000004584 weight gain Effects 0.000 claims description 7
- 235000019786 weight gain Nutrition 0.000 claims description 7
- 239000012298 atmosphere Substances 0.000 claims description 6
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 claims description 6
- 235000020235 chia seed Nutrition 0.000 claims description 6
- 238000004049 embossing Methods 0.000 claims description 6
- 239000011261 inert gas Substances 0.000 claims description 6
- 235000021388 linseed oil Nutrition 0.000 claims description 6
- 239000000944 linseed oil Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 5
- 229940098465 tincture Drugs 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 241001234745 Camelina Species 0.000 claims 8
- 241000218236 Cannabis Species 0.000 claims 3
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 claims 2
- 239000000047 product Substances 0.000 description 50
- 244000197813 Camelina sativa Species 0.000 description 42
- 240000004308 marijuana Species 0.000 description 38
- 238000013270 controlled release Methods 0.000 description 31
- 241000196324 Embryophyta Species 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 238000000576 coating method Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000002798 polar solvent Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000000969 carrier Substances 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 238000004806 packaging method and process Methods 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 230000009969 flowable effect Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 239000000693 micelle Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 229940023488 pill Drugs 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000000506 psychotropic effect Effects 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000012431 wafers Nutrition 0.000 description 6
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 5
- 241000239366 Euphausiacea Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 4
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 4
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 4
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 4
- 108050007331 Cannabinoid receptor Proteins 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 4
- 241000207961 Sesamum Species 0.000 description 4
- 235000003434 Sesamum indicum Nutrition 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006114 decarboxylation reaction Methods 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 239000002621 endocannabinoid Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000021436 nutraceutical agent Nutrition 0.000 description 4
- 238000003305 oral gavage Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 235000007586 terpenes Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229920001800 Shellac Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000010460 hemp oil Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000004208 shellac Substances 0.000 description 3
- 229940113147 shellac Drugs 0.000 description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
- 235000013874 shellac Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 101100099050 Mus musculus Tead2 gene Proteins 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 244000294611 Punica granatum Species 0.000 description 2
- 235000014360 Punica granatum Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 244000213578 camo Species 0.000 description 2
- 229960003453 cannabinol Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 235000014595 Camelina sativa Nutrition 0.000 description 1
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 241000722721 Capparis Species 0.000 description 1
- 235000017336 Capparis spinosa Nutrition 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 241000266847 Mephitidae Species 0.000 description 1
- 229920003107 Methocel™ A15C Polymers 0.000 description 1
- 229920003106 Methocel™ A4C Polymers 0.000 description 1
- 229920003108 Methocel™ A4M Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019495 Pecan oil Nutrition 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- ZZMNWJVJUKMZJY-AFHBHXEDSA-N Sesamolin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-AFHBHXEDSA-N 0.000 description 1
- ZZMNWJVJUKMZJY-UHFFFAOYSA-N Sesamolin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-UHFFFAOYSA-N 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BTNNPSLJPBRMLZ-UHFFFAOYSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(CCOP(O)(O)=O)=C(C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000010474 borage seed oil Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 1
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000010627 cedar oil Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000010638 cranberry seed oil Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000000911 decarboxylating effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 230000008918 emotional behaviour Effects 0.000 description 1
- 239000010776 emu oil Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 102000006966 enzyme regulator activity proteins Human genes 0.000 description 1
- 108040000578 enzyme regulator activity proteins Proteins 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000012787 harvest procedure Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 238000010147 laser engraving Methods 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000019508 mustard seed Nutrition 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 235000021232 nutrient availability Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000010470 pecan oil Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000010491 poppyseed oil Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000013526 red clover Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000010667 rosehip oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000014268 sports nutrition Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009489 vacuum treatment Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 239000010508 watermelon seed oil Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195727 α-lactose Natural products 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- Cannabinoid molecules such as tetrahydrocannabinol (THC), cannabidiol (CBD) cannabigerol (CBG), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabinchromene (CBC), and cannabigerolic acid (CBGA), are known to cause a variety of therapeutic and psychotropic effects when administered to a subject.
- Cannabinoids from the plant genus Cannabis could be considered a type of natural health product, but historically they have not been legally available.
- the laws which have criminalized possession or use of cannabis have been the primary restraint. These laws were put in place apparently to control the use of one specific cannabinoid, delta-9 tetrahydrocannabinol (THC), which causes a mild temporary psychotropic effect in users.
- THC delta-9 tetrahydrocannabinol
- cannabinoids which are devoid of psychotropic effect include but are not limited to tetrahydrocannabinolic acid (THCA), cannabinolic acid (CBNA), cannabidiolic acid (CBDA) and cannabigerolic acid (CBGA) and the de-carboxylated derivatives cannabinol (CBN), cannabidiol (CBD) and cannabigerol (CBG).
- THCA tetrahydrocannabinolic acid
- CBDNA cannabinolic acid
- CBDA cannabidiolic acid
- CBD cannabigerolic acid
- CBN de-carboxylated derivatives cannabinol
- CBD cannabidiol
- CBD cannabigerol
- Cannabinoids are key players in biological systems and bind to receptors in the body known as cannabinoid receptors which have been implicated in a variety of physiological functions, including appetite, pain, emotional behavior (mood), memory, and inflammation.
- CB1 and CB2 There are currently two known well defined subtypes of cannabinoid receptors, called CB1 and CB2.
- the CB1 receptor (CB1R) is expressed mainly in the brain (central nervous system or "CNS"), and also in the lungs, liver and kidneys.
- the CB2 receptor (CB2R) is expressed mainly in the immune system and in hematopoietic or blood cells.
- cannabinoid molecules have traditionally been administered via inhalation, for example by smoking or heating and inhaling the vapours of cannabis plants or cannabis extracts. Oral administration of such molecules, as compared with administration via inhalation, can provide improved consistency of dosing, more discreet administration, and increased convenience for users.
- cannabinoid formulations for oral administration providing consistency of dosing and discreet administration.
- cannabinoid formulations for oral administration comprising: one or more cannabinoids selected from the group consisting of: 0.1 100 mg tetrahydrocannabinol (THC); 0.1 750 mg
- THCA tetrahydrocannabinolic acid
- CBD cannabidiol
- CBDA cannabidiolic acid
- CBG cannabigerol
- a lipid carrier comprising one or more lipids selected from the group consisting of: camelina oil; a marine phospholipid; a krill oil; a fish oil; chia seed oil; flaxseed oil; an oil comprising an omeg-3 to omega-6 ratio of about 1.0 or higher, about 1.5 or higher, about 2.0 or higher, or about 2 2 or higher; a hydrolyzed oil; a vegetable oil; hemp oil; an oil containing medium-chain fatty acids (MCFAs); and an oil containing long-chain fatty acids (LCFAs).
- MCFAs medium-chain fatty acids
- LCFAs long-chain fatty acids
- the lipid carrier comprises or consists of camelina oil.
- one or more of the one or more cannabinoids is dissolved and/or suspended in the lipid carrier.
- the cannabinoid formulation is in a unit dosage form selected from a pill, tablet, capsule, film, wafer, lollipop, lozenge, oil, tincture, or syrup.
- the cannabinoid formulation is an orally disintegrating pill, tablet, capsule, film, or wafer.
- the cannabinoid formulation is a pill or tablet and further comprises an enteric coating for containing the one or more cannabinoids and the lipid carrier.
- the cannabinoid formulation is a pill, tablet, or capsule and further comprises an outer shell that is substantially opaque to one or both of ultraviolet and visible light.
- the cannabinoid formulation further comprises a further carrier oil.
- the cannabinoid formulation further comprises a stabilizer.
- the lipid carrier is present in the form of an emulsion.
- the emulsion is a nanoemulsion.
- the formulation upon administration of the cannabinoid formulation to a subject, a target bioavailability is achieved.
- the formulation comprises a first unit dose amount of a dosed cannabinoid, further wherein the administration is by oral administration, and wherein the target bioavailability is a bioavailability of THC or a THC liver metabolite which is greater than a baseline bioavailability, the baseline bioavailability being that achievable from oral administration to the subject of a control composition containing the first unit dose amount of the dosed cannabinoid in a carrier comprising at least 90%, or consisting of, sesame oil.
- the dosed cannabinoid is THC and wherein the cannabinoid formulation comprises about 30-50% of the unit dose amount of THC in an emulsion.
- the target bioavailability is a THC or THC liver metabolite bioavailability in the subject that is at least 140%, as measured by subject Cmax and/or subject AUC, of the baseline bioavailability.
- the target bioavailability is a THC or THC liver metabolite bioavailability in the subject that is: (i) at least 108.5%, at least 146.9%, at least 159.6%, or at least 200%, as measured by subject Cmax, and/or (ii) at least 144.3%; at least 159.6%, at least 200%, or at least 252.1%, as measured by subject AUC, of the baseline bioavailability.
- the target bioavailability is a bioavailability of: THC; 11- OH-THC; and/or THC-COOH.
- one or more of the cannabinoids is in the form of an organic solvent-based extract of cannabis.
- CBD cannabigerolic acid
- THCV tetrahydrocannabivarin
- the cannabinoid formulation comprises CBD in an amount between 10-50 mg.
- the cannabinoid formulation comprises 25 mg CBD.
- the cannabinoid formulation comprises 500 mg CBD.
- the cannabinoid formulation comprises the cannabinoid is evenly dispersed within at least a portion of the unit dosage form.
- the cannabinoid formulation comprises a signifier signifying a cannabinoid dosage is associated directly with the unit dosage form by embossing, or by colour, pattern, or shape feature.
- the signifier is adapted to be directly interpreted by a consumer and/or is a machine- readable code.
- the unit dosage form is contained in an individual blister pack sealed in an inert gas atmosphere comprising little or no oxygen.
- the lipid carrier is present in the form of a nanoemulsion comprising lipid particles having an average particle size of about 20-100, 20-200, 20-300, 20-400, 20-500, 20-600, 100-300, 200-500, or 100- 600nm.
- the lipid carrier comprises MCFAs comprising or consisting of 12- 16 carbon atoms or LCFAs comprising or consisting of 13 or more carbon atoms.
- the cannabinoid formulation comprises an enteric coating for containing the one or more cannabinoids and the lipid carrier, wherein the enteric coating degrades, dissolves, or otherwise provides a release of the cannabinoid and the lipid carrier in an environment having a pH value of below about 5.5, at about 5.5 or greater, at about 6.0 to about 6.5, at about 6.5 to 7.5, or greater than about 7.5.
- a method of administering one or more cannabinoids to a subject comprising orally administering to the subject a formulation comprising one or more cannabinoids selected from the group consisting of: 0.1 - 100 mg tetrahydrocannabinol (THC); 0.1 - 750 mg tetrahydrocannabinolic acid (THC A); 0.1 - 750 mg cannabidiol (CBD); 0.1 - 750 mg cannabidiolic acid (CBD A); and 0.1 - 750 mg cannabigerol (CBG); 1 - 750 mg cannabinchromene (CBC); and a lipid carrier comprising one or more lipids selected from the group consisting of: camelina oil; a marine phospholipid; fish oil; krill oil; flaxseed oil; an oil comprising an omeg-3 to omega-6 ratio of about 1.0 or higher, about 1.5 or higher, about 2.0 or higher, or about
- the lipid carrier comprises or consists of camelina oil.
- administering comprising orally administering to the subject a cannabinoid formulation as described herein.
- the subject has a disease or disorder treatable by the administration of the one or more cannabinoids.
- the disease or disorder is selected from the group consisting of: pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes, metabolic syndrome, nausea (acute or anticipatory), epilepsy, spasticity, schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, bacterial and/or fungal infection, fibromyalgia, appetite enhancement, appetite suppression, and any combination thereof.
- the disease or disorder is selected from the group consisting of: pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes, metabolic syndrome, nausea (acute or anticipatory), epilepsy, spasticity, schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, fibromyalgia, appetite enhancement, appetite suppression, and any combination thereof.
- the formulation for oral administration comprises a unit dose or combination dose of cannabinoid(s) selected from the list consisting of (each cannabinoid milligram amount about or equal to):
- THC tetrahydrocannabinol
- LCT oral long-chain triglyceride
- FIG. 2 Plasma concentration-time profile of THC following oral gavage of THC (12 mg/kg) formulated with four different carrier oils (sesame, krill, camelina and emulsified camelina oil). Data is shown as mean +/- S.E.M.
- FIG. 3 Plasma concentration-time profile of 11 -OH- THC following oral gavage of THC (12 mg/kg) formulated with four different carrier oils (sesame, krill, camelina and emulsified camelina oil). Data is shown as mean +/- S.E.M.
- FIG. 4 Plasma concentration-time profile of THC-COOH following oral gavage of THC (12 mg/kg) formulated with four different carrier oils (sesame, krill, camelina and emulsified camelina oil). Data is shown as mean +/- S.E.M. DETAILED DESCRIPTION OF THE INVENTION
- cannabinoids and carrier oils in combination has yet to be fully explored.
- the invention herein is directed to novel combinations comprising A) one or more carrier oils, and B) one or more cannabinoids, in oral formulation.
- Such products are useful as health products, dietary supplements, and for treatment of human diseases and disorders.
- the invention herein provides novel oral formulations comprising a combination of one or more cannabinoids with one or more lipid carriers.
- the invention has a variety of advantages, including a surprising increase in cannabinoid bioavailability for the treatment of human diseases and disorders.
- the oral formulation combinations provided herein demonstrate increased bioavailability of cannabinoids for the treatment of pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes and metabolic syndrome, acute and anticipatory nausea, epilepsy, spasticity,
- schizophrenia, bi-polar disorder, cancer and neoplasia chronic pain, osteoarthritic pain, bacterial and/or fungal infection, fibromyalgia, appetite suppression, and/or to act as an anti -proliferative agent.
- Bioavailability refers to the fraction or dose of an administered substance capable of being absorbed by the body’s circulatory system and available for use or storage by a body (e.g., a cannabinoid). Bioavailability may be measured by calculating the concentration of a substance administered to a body over time.
- Cmax is a term used in pharmacokinetics refers to the maximum concentration that a compound/drug achieves in tested area after the drug has been administrated. The Cmax is often measured in an effort to show bioequivalence between a generic and innovator drug product.
- AUC area under the curve
- AUC is proportional to the total amount of a compound absorbed by the body for a dose of a compound
- Cannabinoid refers to a chemical compound that is capable of acting on cannabinoid receptors, for example in the brain. Cannabinoids may be produced naturally in the body
- Cannabinoids produced by cannabis during its cultivation and growth include tetrahydrocannabinolic acid (THCA), cannabinolic acid (CBNA), cannabidiolic acid (CBDA), cannabichromenic acid (CBCA), and cannabigerolic acid (CBGA).
- THCA tetrahydrocannabinolic acid
- CBDNA cannabinolic acid
- CBDA cannabidiolic acid
- CBCA cannabichromenic acid
- CBDA cannabigerolic acid
- cannabinoid may also refer to the corresponding decarboxyl ated moieties, tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabinchromene (CBC) and cannabigerol (CBG), (each of which may be derived from its parent compound by mild heating typically above l05°C), and the corresponding liver metabolites that result upon oral consumption by humans of these compounds, such as but not limited to 1 l-OH-THC and THC-COOH (also known as 1 l-Nor-9-carboxyTHC).
- Cannabinoids may be synthesized by chemical or biological methods.
- Phytocannabinoids may be distinguished from endocannabinoids which are chemically distinct, are synthesized in mammalian cells from lipids and other macromolecule precursors, which are not phytocannabinoids, and which may be endogenous ligands of the CB1 and/or CB2 receptors.
- Cannabis as used herein includes all members of the Cannabis genus, including without limitation Cannabis sativa, Cannabis indica, Cannabis ruderalis, and hybrids thereof.“Cannabis” also includes Charlotte’s Web and other high CBD, low THCA plant varieties.
- “Defined dose” means a dose of one or more active ingredients (typically cannabinoids) which has been selected during the production process and may be signified to a consumer by a signifier associated with the object.
- active ingredients typically cannabinoids
- Effective dose may refer to the amount of a cannabinoid substance sufficient to induce a change in an individual user.
- An effective dose may also mean an amount of a cannabinoid substance that is needed to provide a desired level of said cannabinoid in the bloodstream of an individual user to provide a desired response.
- An effective dose can be administered in one administration, or through multiple administrations of an amount that total an effective dose.
- the effective dose may be the result of empirical and/or individualized (case-by-case) determination on the part of an individual user.
- Enteric coating refers to a barrier applied to an orally delivered substance that prevents or delays its dissolution or disintegration in the gastric environment. Enteric coatings can protect an orally delivered substance from the acidity of the stomach, protect the stomach from detrimental effects of an orally delivered substance, or delay the release of an orally delivered substance until after the stomach (ex. intestinal tract). Examples of enteric-coated dosage forms include without limitation tablets, mini-tablets, pellets, granules, capsules, gel capsules.
- Embodision refers to a mixture of two or more immiscible liquids in which one is present as droplets distributed throughout the other.
- the average droplet size in an emulsion may be between 100-1000 nm.
- “Fatty acid” refers to a carboxylic acid with an aliphatic chain, which may be either saturated or unsaturated.
- the aliphatic chain may be short, medium, or long depending on the number of carbon atoms.
- short chain fatty acids may comprise five or fewer carbon atoms
- medium chain fatty acids may comprise 6-12 carbon atoms
- long chain fatty acids may comprise 13 or more carbon atoms.
- “Lipid carrier” refers to lipid-based drug delivery systems including without limitation emulsions, nanoemulsions, lipid nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers. Lipid carriers can be used to increase solubilization and absorption of hydrophobic compounds, which may result in enhanced bioavailability. Suitable lipids for use in formulating lipid carriers of the invention include, without limitation, camelina oil, marine phospholipids.
- “Liposome” means a vesicle, which may be spherical, having at least one lipid bilayer. Liposomes can be used as a vehicle for delivery of nutrients and/or pharmaceutical agents.
- “Micelle” means an aggregate (or supramolecular assembly) of surfactant molecules dispersed in a liquid colloid.
- Nanoemulsion refers to a mixture of two or more immiscible liquids in which one is present as nano-sized microscopic droplets distributed throughout the other.
- the average droplet size in a nanoemulsion is usually between 20-600 nm.
- Oral Formulation means a formulation which is conveniently administered orally to a human subject.
- PD Pharmacodynamic parameters
- PK concentration-versus-time curve
- Psychotropic dose means a dose of a substance capable of affecting a user’s mental state.
- Examples of psychotropic cannabinoids include without limitation THC, cannabinol (CBN).
- “Unit dosage form” or“UDF” means a physically fixed unit dose of a formulation which is conveniently consumed by a consumer in unit form (e.g. requires no measuring or adjusting of dosage before consumption). A consumer may consume one or more UDFs at a time.
- the unit dosage forms of the invention may comprise a lipid carrier, which may be formulated from one or more lipids including, without limitation, camelina oil and/or a marine phospholipid.
- Camelina oil is an edible oil derived from the seeds of Camelina sativa. Camelina oil has been found to contain high amounts of omega - 3 fatty acids and vitamin E, making it suitable for use as a nutritional supplement and as a general purpose oil. Due to its high vitamin E content, Camelina oil may be used as an antioxidant and as an anti-inflammatory. Camelina oil may also be prepared as an extract of a cultivated Camelina sativa plant crop.
- Phospholipid extracts derived from natural marine or aquatic sources have been shown to possess a variety of nutraceutical and/or therapeutic properties. These marine extracts may comprise a variety of phospholipids, fatty acid, metals, and flavonoid compounds. Examples of suitable marine phospholipids for use in formulating the lipid carriers of the present invention are further described in U.S. patent nos. 8,680,080 B2, 8,383,675 B2, and 8,278,351 B2 and others in the name of Neptune Tech and Bioresources Inc., all of which are incorporated herein by reference in their entirety.
- the unit dosage forms of the invention may further comprise a defined dose of one or more cannabinoids selected from among the group consisting of:
- THCA tetrahydrocannabinolic acid
- THC tetrahydrocannabinol
- CBDA cannabidiolic acid
- CBD cannabidiol
- CBD cannabigerol
- the cannabinoid(s) may be prepared as an extract of a cultivated cannabis plant crop (as described further below), or they may be synthetically prepared in a chemical process (as for example in patent applications WO2014134281, W02015068052, W02016030828 and others in the name of Full Spectrum Laboratories Limited (Dublin IE)), all of which are incorporated by reference in their entireties.
- the composition may also comprise terpenes and other organic molecules co-extracted in the process.
- the unit dosage forms may also comprise diverse additional features which may include an anti -oxidant, other pharmaceutically acceptable additives, a carrier oil, an outer shell that is substantially opaque to one or both of ultraviolet and visible light, an enteric-coating, and/or a signifier which signifies the cannabinoid dosage of the unit dosage form, such as a signifier generated by embossing, or by colour, pattern or shape feature, which signifier may be adapted to be directly interpreted by a consumer and/or is a machine-readable code.
- an anti -oxidant other pharmaceutically acceptable additives
- a carrier oil an outer shell that is substantially opaque to one or both of ultraviolet and visible light
- an enteric-coating and/or a signifier which signifies the cannabinoid dosage of the unit dosage form, such as a signifier generated by embossing, or by colour, pattern or shape feature, which signifier may be adapted to be directly interpreted by a consumer and/or is a machine-readable code.
- the formulation consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG, combined with a specific carrier oil, a particular lipid particle size, and a specific coating.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- cannabinoids which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
- the oral formulations of the present invention may be used for the treatment or amelioration in humans and other animals of a range of diseases and conditions.
- the inventors have identified the advantages of the proposed novel combinations based on a variety of technical assessments which demonstrate surprising effects of the oral combinations on cannabinoid bioavailability relevant to the treatment or amelioration of a range of diseases and conditions. These assessments, described below, include 1) Identifying improved bioavailability and enhanced PK/PD of the combinations in in vivo models; and 2) By providing animal (including human) testing in complex diseases and disorders and models of complex diseases and disorders.
- Cannabinoids such as THC, CBD, CBG, and CBN interact with the body in different ways, leading to a variety of cannabinoid-associated effects.
- ingestion of THC may lead to increased relaxation or stress reduction, enhanced feelings of well-being and euphoria.
- THC has been used to treat ailments such as neuropathic pain, multiple sclerosis, Crohn’s disease, in cancer patients to increase appetite and reduce nausea, inflammation (swelling and redness), and muscle control problems.
- CBD has been shown to alleviate certain adverse effects of THC experienced by some consumers.
- CBD can act as a sedative, anti -convulsive, anti-inflammatory, anti-oxidant, or anti-depressant.
- CBG is an adrenergic, serotonergic, enzyme modulator, slow the proliferation of cancer cells, reduces intraocular eye pressure caused by glaucoma, inflammatory bowel disease, Crohn’s disease and analgesic, while CBN may regulate the immune system and induce sleep.
- CBC is a non-psychoactive cannabinoid widely considered to interact with the endocannabinoid system (ECS) through stimulation of the body’s naturally occurring endocannabinoids, anandamide and 2-AG, and is a known agonist to TRPV1 and TRPA1 receptors (A. A. Izzo et al.: Br. J.
- CBC is thought to be a selective CB2 receptor agonist which may have therapeutic implications for the treatment of pain and inflammatory conditions through CB2-mediated regulatory pathways (M. Udoh et al.: Br. J. Pharmacol. (2019).
- CBC co-administered with THC produced an enhanced anti-inflammatory effect, suggesting a potential pharmacokinetic interaction between the two molecules (G. T. DeLong et al.: Drug Alcohol Depend. 112, 126 (2010).
- CBC has been identified as a molecule of interest for various therapeutic applications including pain, inflammation, digestive and gastrointestinal disorders. Furthermore, it is known to have antibacterial and antifungal effects, and could potentially contribute to the regeneration of brain cells, which possibly has implications in the treatments of multiple sclerosis bacterial and/or fungal infection,, fibromyalgia, dementia,
- Alzheimer’s and other neurodegenerative related conditions are associated with Alzheimer’s and other neurodegenerative related conditions.
- Unit dosage forms of the present invention may be applicable to a wide range of diseases or conditions, including without limitation, inflammatory, immune, neurological, psychiatric disorders, seizures/epilepsy, anxiety and stress disorders, malignancies, metabolic disorders, nutritional deficiencies, infectious diseases, types of gastrointestinal disorders, sleep disorders, cardiovascular disorders, complex chronic diseases, and various types of pain, including chronic and neuropathic pain.
- unit dosage forms of the present invention may be applicable, although not only, to at least one of pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes and metabolic syndrome, acute and anticipatory nausea, epilepsy, spasticity, schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, bacterial and/or fungal infection, fibromyalgia, all the foregoing in acute and/or chronic presentation, and may be further used to induce appetite suppression and/or act as an anti -proliferative agent.
- compositions and methods of the invention feature a combination of lipid carrier(s) and one or more cannabinoids.
- the combinations of the invention may comprise one or more cannabinoids selected from among the group consisting of:
- THCA tetrahydrocannabinolic acid
- THC tetrahydrocannabinol
- CBDA cannabidiolic acid
- CBD cannabidiol
- CBC cannabinchromene
- CBD cannabigerol
- the oral combinations may comprise a defined dose selected from the following ranges (which may be referred to as“low dose”): about 0 mg, 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between 0 mg and 100 mg THC, about 0 mg, 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between Omg and 100 mg THCA, about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6,
- the oral combinations comprise about 0 mg, 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or about any 1 mg interval between 0 mg and 100 mg of one of the foregoing compounds.
- the oral combinations of the present invention have defined dosages for more than one of the foregoing compounds.
- the oral combinations comprise from about 0 mg - 1 mg, or any 0.1 mg interval therebetween THC, about 0 mg, about 9 mg, about 90 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between 0 mg and 100 mg, about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between 0 mg and 100 mg CBD, and/or about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4,
- the oral combinations comprise from about 0 mg, about 9 mg, about 90 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between 0 mg and 100 mg CBDA.
- the oral combinations comprise from about 0 mg, about 9 mg, about 90 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between 0 mg and 100 mg THC, 0 mg - 1 mg THCA, or any 0.1 mg interval therebetween, about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between Omg and 100 mg CBD, and
- compositions are substantially free of THC-type cannabinoid compounds.
- the oral combinations comprise from about 0 mg - 1 mg, or any 0.1 mg interval therebetween THC, 0 mg - 1 mg THCA, or any 0.1 mg interval therebetween, about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between Omg and 100 mg CBD, and about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between Omg and 100 mg CBDA.
- the oral combinations may comprise a defined dose selected from the following ranges (which may be referred to as“high dose”): about 10 mg, 15, 20, 25, 30, 40,
- any 10 mg interval between 0 mg and 750 mg THCA about 0 mg, 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between 0 mg and 100 mg THC, about 10 mg, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about any lOmg interval between Omg and 750 mg CBD, and/or about 10 mg, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about any lOmg interval between Omg and 750 mg CBD, and/or about 10 mg, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg,
- the oral combinations comprise about 10 mg, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about 10 mg interval between 0 mg and 750 mg of one of the foregoing compounds.
- the oral combinations of the present invention have defined dosages of more than one of the cannabinoids.
- the compositions are substantially free of THC-type cannabinoid compounds.
- the oral combinations comprise from about 0 mg - 1 mg, or any 0.1 mg interval therebetween THC, 0 mg - 1 mg THCA, or any 0.1 mg interval therebetween, plus CBD in the amount of about 0 mg, about 25 mg, about 75 mg, about 10 mg, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about 10 mg interval between 0 mg and 750 mg, and/or CBDA in the amount of about 0 mg, about 25 mg, about 75 mg, about 10 mg, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg.
- the oral combinations described herein comprise an“effective” amount of one or more of the cannabinoid ingredients described herein.
- the term“effective amount” refers to an amount of the one or more cannabinoid ingredients sufficient to induce a response in an individual user, either subjectively or objectively determined.
- An effective amount also means an amount of the one or more cannabinoid ingredients that is needed to provide a desired level of cannabinoid(s) in the bloodstream of an individual user to provide an anticipated physiological response.
- An effective amount of a cannabinoid ingredient can be administered in one administration, or through multiple administrations of an amount that totals an effective amount, preferably within a 24-hour period.
- the effective amount can be the result of empirical and/or individualized (case-by-case) determination on the part of the individual user.
- a therapeutically effective amount of said one or more cannabinoid ingredients may be in the range of about 1 mg to 2,000 mg, or any 1 mg or 10 mg interval there between total cannabinoids per day.
- an effective amount of one or more cannabinoid ingredients may be in the range of about 1 mg - 5 mg, or any 1 mg or 0.1 mg interval therebetween per day. For example, for an adult, about 1-2 mg, or 0.1 mg interval therebetween, a day total cannabinoids may provide a very low-end dose below the psychoactive threshold.
- an effective amount of THC may be in the range of about 5 mg - 25 mg, or any 1 mg interval therebetween. For example, most vapers inhale about 10 to 30 mg of THC to establish a mild, temporary, psychoactive effect.
- the oral formulation may contain THC in an amount of 25 mg to 100 mg.
- a composition of the present invention may comprise THCA in an amount between 5-200 mg, THC in an amount less than 1.0 mg, and CBDA in an amount between 0.1-600 mg, and have a total mass of 100-750 mg.
- a composition of the present invention may comprise THCA in an amount less than 5.0 mg, THC in an amount between 5-30 mg, and CBD in an amount between 0.1-600 mg, and have a total mass of 100-750 mg.
- a composition of the present invention may comprise THCA in an amount less than 1.0 mg, THC in an amount less than 1.0 mg, and CBD in an amount between 5- 600 mg, and have a total mass of 100-750 mg.
- a composition of the present invention may comprise THCA in an amount less than 1.0 mg, THC in an amount less than 1.0 mg, and CBG in an amount between 5- 600 mg, and have a total mass of 100-750 mg.
- an effective amount of CBD for treating conditions or disorders disclosed elsewhere herein may be in the low dose range of about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between 0 mg and 100 mg per day.
- the low dose amount of CBD may be about 50 mg per day.
- a recommended CBD dosage standard may be about 25 mg of CBD taken twice a day.
- an effective amount of CBD for treating conditions or disorders disclosed elsewhere herein may be in the high dose range of about 50-2000 mg/day or higher.
- Such effective amounts may be provided by ingestion of multiple oral dosage forms comprising CBD in the amount of, about 50 mg, about 75 mg, about 100 mg, 200 mg, 250 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about any 10 mg interval between 100 mg and 750 mg.
- an effective amount of THCA may be in the range of about 0 mg, about 9 mg, about 90 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between 0 mg and 100 mg.
- only one cannabinoid will be present at a physiologically relevant level, in other embodiments two or more cannabinoids may be present at physiologically relevant levels.
- the second cannabinoid may be one previously cited, or may be an alternative cannabinoid which may also be isolated from or extracted from cannabis, or may be a simple chemical derivative thereof.
- Tables 1A-1C provide examples for preferred embodiments.
- Table 1B 250 mg capsule (low dose; lOmg THC maximum)
- Table 1C 1000 mg capsule (high dose)
- cannabinoid required for an effective dose in an individual will depend upon numerous factors, e.g. type of cannabinoid(s) and type or combination of lipid carrier(s), type of lipid carrier, and the effect of the lipid carrier-cannabinoid combination on bioavailability.
- This disclosure provides UDFs suitable to obtain an effective dose which can be determined subjectively by the user or objectively by methods known to those skilled in the art.
- An achievement of the invention is that by using the UDFs of the invention, users and medical advisors for the first time have knowledge of and certainty with the preferred doses of cannabinoid they are employing with the lipid carrier. This is preferably achieved with a signifier identifying dosage of one or more components, as detailed further below.
- the cannabinoid(s) for use in the present UDFs may be prepared by a variety of methods. It may be provided in the original plant form, preferably dried and cured into a flowable powder suitable for encapsulating.
- An alternative preferred method is by extraction from a cultivated cannabis crop.
- Organic extraction is a preferred method, although aqueous extraction, typically employed to prepare hashish, is also possible. Organic extraction can be performed with a wide variety of organic solvents or super-critical carbon dioxide, and at a variety of temperatures and under a variety of conditions. (Fairbairn and Liebmann (1973) J. Pharm. Pharmac. 25: 150-155; Romano and Hazekamp (2013) Cannabinoids.
- the resulting organic solvent-based extract can be, at room temperature, a liquid oil, or solid form wax, budder, or shatter depending on the conditions employed (which significantly impact the other plant alkyloids and polymers extracted by the process).
- cannabinoids were extracted from dried plant material. Fairbairn and Liebmann (1973), incorporated herein in its entirety.
- Modem techniques may extract over 90%.
- the unpredictability of cultivated cannabis provides another potential challenge to formulation of the disclosed UDFs.
- the most common varieties C. sativa , C. indica and C. ruderalis have distinct (but overlapping) ranges of cannabinoids.
- Varieties and strains which are crossed or hybridized generate further different cannabinoid ratios.
- the cannabinoid ratios and overall amounts within a single variety are strongly influenced by the conditions of cultivation, especially light cycle, temperature, soil condition, nutrient availability, timing of harvest and pathogen exposure.
- the result is that a cultivated cannabis plant can have, by dry weight, anywhere from 0% up to greater than 30% of selected cannabinoids, and the ratios between individual cannabinoids can be highly diverse.
- Preferred cannabis sp. cultivars for use preparing cannabinoid extracts include: Acapulco Gold;sammlungn red; Columbian; Hawaiian; Jamaican gold; Mexican red;
- Preferred for cultivation in Canada are: Altair, Angie, CS, Carmagnola, Carmen, Deni, ESTA-l, FINOLA, Fasamo, Fedrina 74, Felina 34, Fibranova, Fibriko, Fibrimon 24, Fibrimon 56, Georgina, GranMa, Grandi, Judy, Katani, Kompolti, Kompolti Hibrid TC, Kompolti Sargaszaru, Laura Secord, Lovrin 110, Martha, Petera, Picolo, Quida, UC-RGM, Uniko B, Victoria, and Yvonne.
- Preferred cannabis sp. cultivars for use in preparing CBD extracts that contain little or no THC or THCA include: Charlotte’s Web and cultivars approved in Canada including CFX-l, CFX- 2, CRS-l, Canda, Crag, Joey, USO 14, USO 31, X-59 (Hemp Nut), Delores, Silesia, Alyssa, Zolotonosha 11, Anka, Jutta, CanMa, and Ferimon.
- THCA tetrahydrocannabinolic acid
- cannabidiolic acid tetrahydrocannabinolic acid
- CBD A the non-psychoactive analgesic and anti-inflammatory cannabinoid
- Decarboxylation may be induced by heating over l05°C and/or by exposure to ultraviolet (UV) light.
- UV ultraviolet
- gastric acids do not decarboxylate THCA or CBD A.
- extract preparations of cannabinoid(s) for use in UDFs of the present disclosure are analyzed to determine the precise concentrations of relevant cannabinoids, especially THCA, THC, CBDA and CBD, for use in preparing unit dosage forms of the invention.
- the cannabinoids in the oral formulation of the present invention may be provided as dried plant matter, as extracts of plant matter, or as generated by chemical synthesis.
- a valuable parameter for usefulness is on whether the format is flowable.
- the cannabinoid format is preferably efficient for mixing with other components and for loading into capsules, forming tablets, and the like. Stickiness of powders or high -viscosity of liquids can be a deterrent to efficient preparation.
- the invention therefore takes advantage cannabinoid formats that are sufficiently flowable for use in manufacturing the UDFs described herein. Flowability of dried plant material may be enhanced by appropriate grinding and by addition of excipients, including but not limited to those described herein.
- Oil extracts with hydrophobic components may be mixed with powders to provide a dry flowable powder which can easily be mixed with other UDF components (e.g., US Pat App. Publications 20170232210 and 20160243177).
- oil extracts may be spray dried with flowable particles to create a flowable powder format.
- extracts may be used to produce crystallized pure cannabinoids. Crystallized CBD can be prepared by high-vacuum treatment of extracts, as exemplified at
- Crystallized forms can be rendered into a suitable flowable powder by techniques common in the capsule/tablet industry.
- the oral formulations of the present invention may comprise at least one carrier oil. This feature is particularly advantageous as the carrier oil(s) may increase the bioavailability of one or more cannabinoid ingredients.
- carrier oils may be employed to dissolve, solubilize or otherwise formulate the components of UDFs of the present disclosure into a liquid or semi-solid formulation suitable for manufacturing the oral formulation and unit dosage forms of the invention.
- Carrier oils may comprise short chain, medium chain and/or long chain fatty acids.
- carrier oils comprise, by mass, from about 50% to about 98%, about 75% to about 95%, and preferably about 90% to about 93% of the liquid fill of the UDF.
- the oils may be formulated with the cannabinoid(s) and the other components of the invention through any known formulation process, including but not limited to surfactant mixtures, emulsions, liposomes (e.g. fully encapsulated or lipid- aggregated), and nanoparticles.
- Carrier oil(s) for use in the presently disclosed formulations may be plant-based or animal- based.
- Plant-based carrier oils can be derived from the fatty portions of a plant, for example, from the seeds, kernels or nuts.
- Animal-based carrier oils can be derived from raw animal fat or from the fatty tissues of an animal, for example, the liver.
- a carrier oil of the present invention may exist in a variety of forms.
- a carrier oil may be an oil, fat, wax, or similar product, for example, lecithin.
- a carrier oil may be hydrolyzed, hydrogenated, or non-hydrogenated.
- a hydrolyzed carrier oil refers to a carrier oil that has been split into its component parts in the presence of an aqueous base. Examples of component parts of a carrier oil may include glycerol, fatty acids etc.
- a hydrogenated carrier oil refers to an oil with saturated fatty acids that may be solid at room temperature.
- a non-hydrogenated carrier oil refers to an oil with unsaturated fatty acids that may be a liquid at room temperature.
- a non- hydrogenated carrier oil with unsaturated fatty acids can be chemically changed through the addition of hydrogen to form a hydrogenated carrier oil with saturated fatty acids.
- the carrier may be a bioactive or nutraceutical agent.
- Nutraceutical agents are natural, bioactive chemical compounds that have health promoting, disease preventing or medicinal properties
- oral formulations may comprise one carrier oil.
- oral formulations may comprise a mixture of at least two carrier oils.
- a mixture of carrier oils may comprise plant-based oils, animal-based oils, or a combination thereof.
- one or more carrier oils may be plant-based.
- plant-based carrier oils include without limitation almond oil, apricot kernel oil, avocado oil, borage seed oil, castor oil, chia seed oil, cranberry seed oil, corn oil, coconut oil, hazelnut oil, hemp oil, evening primrose oil, grapeseed oil, jojoba oil, linseed oil, macadamia nut oil, mustard seed oil, sesame oil, olive oil, cotton oil, peanut oil, pecan oil, pomegranate seed oil, poppy seed oil, rosehip oil, soybean oil, sunflower oil, and watermelon seed oil.
- one or more plant-based carrier oils may be an essential oil or volatile oil such as bay oil, bergamot oil, balm oil, cedarwood oil, cherry oil, cinnamon oil, clove oil, peppermint oil, and walnut oil.
- one or more carrier oils may be animal-based.
- animal-based carrier oils include without limitation poultry oil, emu oil, oleo-oil, tallow oil, fish oil, fish liver oil, and cod liver oil.
- one or more carrier oils may comprise one or more long chain fatty acids.
- Long chain fatty acids may have a straight or branched chain preferably comprising 13 or more carbon atoms. Long chain fatty acids are absorbed by the lymphatic system. Formulations comprising one or more long chain fatty acids may therefore improve absorption when combined with certain mixtures of cannabinoid(s) and carrier oil(s).
- one or more carrier oils may comprise one or more medium chain fatty acids. Medium chain fatty acids may have a straight or branched chain preferably comprising 6 - 12 carbon atoms. It is possible to use one or more lengths of fatty acids in combination.
- Carrier oils employed will be safe for human consumption at the dosages provided.
- Camelina oil is widely available from commercial sources including www.threefarmers.ca.
- MCT Oil has naturally occurring fatty acids caprylic acid (C8:0) and capric acid (Cl0:0). MCT Oil may be derived from coconut/palm kernel oil. MCT Oil is widely available from commercial sources including Now Foods (see https://www.nowfoods.com/sports-nutrition/mct-oil-liquid)
- Marine oils are preferred carrier oils in certain embodiments.
- Marine oils comprise oils extracted from ocean organisms including vertebrates (e.g. fish) and non-vertebrates (e.g.
- a preferred carrier oil for use in the invention is oil extracted from krill.
- Neptune Krill Oil (NKO) has unique fatty acid profile, which includes EPA and DHA, plus phospholipids.
- NKO naturally has astaxanthin, a free radical scavenger and immune-supporting carotenoid.
- Krill oil, in particular NKO is widely available from commercial sources including https://www.nowfoods.com/supplements/.
- the carrier oils comprise preferred ratios of omega-3 oils to omega-6 oils (on a weight per weight basis unless otherwise indicated).
- carrier oils comprise a preferred omega-3 to omega-6 ratio (on a weight per weight basis) of about 1.0 or higher, 1.5 or higher, 2.0 or higher, or 2.2 or higher.
- the invention provides a method for producing an emulsion of lipid carrier(s) and cannabinoid.
- An emulsion may be generated simply by mixing a food grade surfactant with the lipid carrier and the cannabinoid formulation.
- Surfactants such as LabrasolTM are satisfactory.
- Gentle agitation is sufficient to generate a surfactant mixture of the invention which is an emulsion, or a surfactant mixture that becomes an emulsion upon exposure to the aqueous environment of the gastric tract.
- the method of generating oil-in-water emulsions generally includes the steps of (i) dissolving one or more cannabinoids and one or more lipid carriers in a polar solvent (e.g. ethanol) to obtain a cannabinoid-lipid carrier-polar solvent solution;
- the average diameter of the droplets in the emulsion is in the range of about 100 nm to 1000 nm.
- the invention provides a method for producing a nanoemulsion of lipid carrier(s) and cannabinoid.
- the method generally including the steps of (i) dissolving one or more cannabinoids and one or more lipid carrier(s) in a polar solvent (e.g. ethanol) to obtain a cannabinoid-lipid carrier-polar solvent solution; (ii) injecting the cannabinoid-lipid carrier-polar solvent solution into distilled water and blending to obtain a cannabinoid-lipid carrier-polar solvent emulsion; and (iii) removing the polar solvent to obtain a concentrated emulsion of lipid carrier/cannabinoid.
- a polar solvent e.g. ethanol
- injecting the cannabinoid-lipid carrier-polar solvent solution into distilled water and blending to obtain a cannabinoid-lipid carrier-polar solvent emulsion
- removing the polar solvent to obtain a concentrated emulsion of lipid carrier/cannabinoid
- nanoemulsion is in the range of about 20 nm to 600 nm.
- the average diameter of the droplets in the emulsion is in the range of about 50 nm to 150 nm.
- any method may be employed to generate an emulsion or nanoemulsion.
- many methods are available for generating emulsions and/or nanoemulsions, such as those found in Jaiswal, M. et al. 2015“Nanoemulsion: An Advanced Mode of Drug Delivery System” (3 Biotech, 5(2): 123-127), and Ting, Y. et al. 2013“Emulsion in Oral Delivery of Bioactive Lipophilic Phytochemicals” (from the book: Nutrition, Functional and Sensory Properties of Foods); see also Singh Y. et al. 2017 “Nanoemulsion: Concepts, development and applications in drug delivery” (J Control Release, 252:28-49), all of which publications are incorporated herein in their entireties.
- the invention provides a method for producing a liposomal formulation of lipid carrier(s) and cannabinoid.
- the method generally including the steps of (i) dissolving one or more lipid carrier(s) and one or more cannabinoids in a polar solvent (e.g.
- the average diameter of the liposomes in the suspension is in the range of about 50 nm to 1000 nm.
- the invention provides a method for producing micellar formulations of lipid carrier(s) and cannabinoid.
- the method generally including the steps of (i) dissolving one or more lipid carrier(s) and one or more cannabinoids in a water miscible solvent to obtain a solution containing a mixture of lipid carrier(s) and cannabinoid; (ii) injecting the mixture into distilled water to obtain an aqueous miscible solvent suspension of micelles; and (iii) removing the water miscible solvent to obtain a concentrated micellar formulation.
- the average diameter of the micelles in the suspension is in the range of about 50 nm to 1000 nm.
- any method may be employed to generate a micelle.
- many methods are available for generating micelles, such as those found in Xu, W. et al. 2013“Polymeric Micelles, a Promising Drug Delivery System to Enhance Bioavailability of Poorly Water-Soluble Drugs” (J Drug Deliv, 340315), incorporated herein in its entirety.
- the methods of the present invention may include one or more additional steps.
- An additional step may include (a) adding a stabilizer, carrier, buffer, excipient, or the like, to a formulation of the present invention; (b) encapsulating a formulation of the present invention.
- Encapsulation of cannabinoid-lipid carrier formulations can take place by trapping or dispersing cannabinoid-lipid carrier formulations within an encapsulating matrix.
- encapsulation involves trapping cannabinoid-lipid carrier formulations within a network of crosslinked polymers.
- encapsulation involves trapping cannabinoid-lipid carrier formulations within a network of non-crosslinked polymers.
- encapsulation involves dispersing cannabinoid-lipid carrier formulations within the crystalline structure of a macromolecule. Examples of crystalline structure-forming
- macromolecules include without limitation sugars, starches, and proteins.
- any chemical analytical method may be employed to determine the amount of the cannabinoids in the preparation used for formulating the LIDF.
- Many methods are available to those skilled in the art, such as those found in Thomas, BF and El Sohly, M 2015“The Analytical Chemistry of Cannabis: Quality Assessment, Assurance, and Regulation of Medicinal Marijuana and Cannabinoid Preparations” (Elsevier). See also Wang et al. (2016) Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry. Cannabis Cannabinoid Res.; 1(1): 262- 271; and Wang et al. (2017) Quantitative Determination of Cannabinoids in Cannabis and Cannabis Products Using Ultra-High-Performance Supercritical Fluid Chromatography and Diode
- Testing may be performed to identify the cannabinoid content of the ground dried plant form, any other solid form or a liquid extract preparation.
- Testing may be required at one step or at multiple steps in the production process. It may be first performed as a batch assay to ascertain amounts of relevant cannabinoids from a particular harvest or extraction process.
- the representative sample and measurement technique must be sufficient to represent all samples of the process batch within the degree of variability tolerated by the overall process, namely +/- 25% of the defined dose of each cannabinoid.
- the cannabinoid preparation may need to be adjusted (either diluted or concentrated) to generate a cannabinoid preparation to meet the tolerance range of volume/dose range for manufacturing specifications of the UDF.
- the operator will have available a variety of cannabinoid diluents or concentrating processes and/or oils of known cannabinoid concentrations to adjust the preparation. Often only one cannabinoid will need to be added, the others being already at satisfactory levels. The operator can determine by simple algorithm the amount of which additives and/or which concentration steps are required to obtain the desired preparation. The final preparation of cannabinoid may again be chemically analyzed. Any final preparation which is not within tolerance levels is discarded or re-processed until desired cannabinoid levels are obtained.
- the final tolerance level is within +/- 25%, preferably within +/- 20%, +/- 15%, +/- 10%, +/- 5%, +/- 2% and most preferably within +/- about 1% of the desired in-going amount of each defined dose cannabinoid in the preparation used for formulating the UDF.
- the UDF is expected to contain a dose of from 80% to 120% of the amount stated on product label. Preferably the range will be significantly more precise.
- a variety of other plant constituents may be extracted from cannabis along with the cannabinoids. It may be desirable to identify and confirm concentrations of these components. Terpenes, chlorophylls, other alkaloids and macromolecules may also be detected by gas chromatography, mass spectroscopy, high-pressure liquid
- the signifier used with the unit dosage form product may also indicate the defined dose of such additional plant components.
- Oral formulations of the invention may optionally further comprise additional components such as but not limited to carrier oils, stabilizers, anti -oxidants, preservatives and excipients, as further described below.
- Excipients may be used for the purpose of stabilizing cannabinoids of the oral dosage forms, or to confer a therapeutic enhancement such as facilitating drug absorption, reducing viscosity, or enhancing solubility.
- Useful excipients include without limitation diluents, dissolving agents, solubilising agents, adjuvants, anti-adherents, binders, coatings, colorants, surfactants,
- bioadhesives polysaccharides, polymers, copolymers, bioavailability enhancing agents,
- Excipients may include one or more pharmaceutically acceptable carriers, diluents, fillers, hinders, lubricants, glidants,
- suitable pharmaceutically acceptable carriers, diluents or fillers for use in the invention include lactose (for example, spray-dried lactose, alpha-lactose, beta-lactose), or other commercially available forms of lactose, lactitol, saccharose, sorbitol, mannitol, dextrates, dextrins, dextrose, maltodextrin, croscarmellose sodium, microcrystalline cellulose (for example, microcrystalline cellulose available under the trade mark Avicel), hydroxypropyl cellulose, L- hydroxypropyl cellulose (low substituted), hydroxypropyl methylcellulose (HPMC),
- lactose for example, spray-dried lactose, alpha-lactose, beta-lactose
- lactose for example, spray-dried lactose, alpha-lactose, beta-lactose
- lactose for example, spray-dried lactose,
- methylcellulose polymers such as, for example, Methocel A, Methocel A4C, Methocel A15C, Methocel A4M), hydroxyethylcellulose, sodium carboxymethylcellulose, carboxym ethylene, carboxymethyl hydroxyethylcellulose and other cellulose derivatives, pre-gel atinized starch, starches or modified starches (including potato starch, com starch, maize starch and rice starch) and the like.
- glidants and lubricants may also be included in the invention.
- Non-limiting examples include stearic acid and pharmaceutically acceptable salts or esters thereof (for example, magnesium stearate, calcium stearate, sodium stearyl fumarate or other metallic stearate), talc, waxes (for example, microcrystalline waxes) and glycerides, light mineral oil, PEG, silica acid or a derivative or salt thereof (for example, silicates, silicon dioxide, colloidal silicon dioxide and polymers thereof, crospovidone, magnesium aluminosilicate and/or magnesium alumina metasilicate), sucrose ester of fatty acids, hydrogenated vegetable oils (for example, hydrogenated castor oil), or mixtures thereof or any other suitable lubricant.
- stearic acid and pharmaceutically acceptable salts or esters thereof for example, magnesium stearate, calcium stearate, sodium stearyl fumarate or other metallic stearate
- talc waxes (for example, microcrystalline waxes) and glycerides
- light mineral oil PEG
- binders may also be present in the invention and non-limiting examples of suitable binders are, for example, polyvinyl pyrrolidone (also known as povidone), polyethylene glycol(s), acacia, alginic acid, agar, calcium carragenan, cellulose derivatives such as ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethylcellulose, dextrin, gelatin, gum arabic, guar gum, tragacanth, sodium alginate, or mixtures thereof or any other suitable
- suitable binders are, for example, polyvinyl pyrrolidone (also known as povidone), polyethylene glycol(s), acacia, alginic acid, agar, calcium carragenan, cellulose derivatives such as ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethylcellulose, dextrin
- Suitable disintegrants may also be present in the invention. Examples include, but are not limited to, hydroxylpropyl cellulose (HPC), low density HPC, carboxymethylcellulose (CMC), sodium CMC, calcium CMC, croscarmellose sodium; starches exemplified under examples of fillers and also carboxymethyl starch, hydroxylpropyl starch, modified starch; crystalline cellulose, sodium starch glycolate; alginic acid or a salt thereof, such as sodium alginate or their equivalents and any combination thereof.
- HPC hydroxylpropyl cellulose
- CMC carboxymethylcellulose
- sodium CMC sodium CMC
- calcium CMC calcium CMC
- croscarmellose sodium starches exemplified under examples of fillers and also carboxymethyl starch, hydroxylpropyl starch, modified starch
- crystalline cellulose sodium starch glycolate
- alginic acid or a salt thereof such as sodium alginate or their equivalents and any combination thereof.
- antioxidant includes any compound or combination of compounds that prevent or slow down oxidation of components caused by the damaging reactive oxygen species (ROS).
- ROS reactive oxygen species
- Any of the known antioxidants may be used, including but not limited to tocopherols, phospholipids (PL), phytosterols, phycocyanin, vitamins E, A and C, betacarotene, coenzyme Q10, fatty acids omega-3, omega-6 and w-9, phytoantioxidants such as polyphenols, terpenes as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, lecithin, sesamin, sesamol, sesamolin, a-tocopherol, g-tocopherol, salicylic acid, ascorbic acid, ascorbyl palmitate, fumaric acid, malic acid, sodium ascorbate and sodium meta-bisulphite, as well as chelating agents such as disodium EDTA.
- nutraceutical dietary supplements may also be employed as anti -oxidants including plants, alga, and lichen and may include one or more extracts of honeybee propolis, red clover, soybean, caper, almond, milk thistle, green tea, pomegranate, orange red, grape seed, bilberry, foti root, ginseng, english ivy, red algae, brown algae, green algae and lichens.
- the total moisture (water) content of the ETDF may be selected to ensure appropriate stability and shelf-life for the product. Those skilled in the art may identify acceptable ranges depending on the form of ETDF selected. Softgels are particularly sensitive to water content as water will weaken and dissolve softgel gelatin capsules. Water content is typically kept below 30% and preferably below 5% of the total mass.
- certain potential contaminants are eliminated, avoided, or present at trace levels considered acceptable for human consumption.
- the preferred embodiments eliminate, avoid or reduce the presence of organic solvents, pest control products, di- acetyl and ammonia.
- At least one emulsifying agent is used to improve the stability of the cannabinoid active ingredients in oral formulations of the present invention.
- the stability of an emulsion refers to the ability of the emulsion to resist change in its properties over time.
- An emulsifying agent may be used to modify a hydrophobic cannabinoid oil so as to enhance hydrophilicity such that the hydrophobic cannabinoid oil is more bio-available.
- emulsifying agents that are safe for human consumption include without limitation, LabrasolTM, xanthan gum, guar gum, alginate, cyclodextrin, lecithin, cellulose, hyaluronic acid, carrageen, monoglycerides, natural emulsifiers, organic emulsifiers.
- oral formulations of the present invention may be formulated with modified- or sustained-release coatings or layers.
- Modified- or sustained-release coatings are designed to delay release of active cannabinoids for a certain period of time, to target release to a certain area of the body, or to maintain a constant drug concentration for a specific period of time with minimal side effects.
- Controlled release can be achieved by coating UDFs using various pharmacological technologies. For example, poly(meth)acrylate coatings have been widely used in the pharmacological industry to achieve targeted and controlled drug release.
- enteric coatings include without limitation hydroxypropyl methylcellulose, poly(meth)acrylates, methyl acrylate-methacrylic acid copolymers, cellulose acetate, cellulose acetate phthalate, polyvinyl acetate phthalate, plastics plant fibres, and other types of coatings.
- enteric coatings may be used to delay release of cannabinoids until they reach the intestine.
- An enteric coating that dissolves at a pH of about 6.0 to 7.0 may be used for this purpose.
- An example of a suitable enteric coating that dissolves in the small intestine but not in the stomach is cellulose acetate phthalate.
- a long-chain fatty acid of specific length shown to be best with the specific cannabinoid or cannabinoids of interest, combined with a specific micellar particle size may be used.
- a long-chain fatty acid of specific length shown to be best with the specific cannabinoid or cannabinoids of interest, combined with a specific micellar particle size combined with enteric coatings designed to place the release of the dosage form to a specific part of the GI tract may be used.
- the UDF meets the requirements of a dissolution or
- a significant drawback to the use of cannabinoid-based products is the lack of a consistent and robust method of delivery.
- the route of administration and formulation can significantly affect the rate of cannabinoid absorption.
- studies show that the bioavailability of THC from inhaled cannabis smoke can fluctuate between 2-56% compared to 4-20% for orally consumed cannabis (Huestis 2007; PMC ID: PMC2689518 and McGilveray 2005; PMID: 16237477, both incorporated by reference in their entireties).
- Smoking can provide a rapid and efficient method of drug delivery from the lungs to the brain but these advantages are offset by the harmful effects of cannabinoid smoke, which are not appealing to many users for health or lifestyle reasons.
- Oral delivery is therefore a common alternative route of administration for cannabinoid products, particularly because cannabinoids can be easily incorporated into food and beverage products or ingested in tablet, pill, capsule, or similar forms.
- cannabinoids Absorption of cannabinoids can be slower when ingested, with lower and sometimes delayed peak cannabinoid concentrations (Ohlsson 1981; PMID: 6261133), incorporated herein in its entirety. Dose, vehicle, and physiological factors such as rates of metabolism and excretion can influence cannabinoid concentrations in circulation. Variable absorption, degradation of cannabinoids in the stomach, and first-pass metabolism to active and inactive metabolites in the liver are the main reasons for the low oral bioavailability of cannabinoids. Effective oral formulations of cannabinoids are therefore essential to maximize their therapeutic effects.
- An advantage of the invention is the improved bioavailability of the claimed oral formulations.
- Historical long chain triglycerides such as sesame oil and other vegetable oils have been added to formulations to help dissolve the lipid soluble cannabinoids
- the potential effect of sesame oil (mostly comprised of long-chain triglycerides (LCT)) on improving bioavailability of oral cannabinoid doses, examining only THC and CBD, was reported in Zgair et al. (2016) Am J Transl Res 20l6;8(8):3448-3459.
- the AUC and Cmax of lipid-based formulations were enhanced over lipid-free formulations (c.f. Zgair Figure l/Table 3 (for THC)).
- AUC area under the curve
- Cmax i.e. the highest concentration of cannabinoid, or a liver metabolite thereof, in the plasma that is measured after a dose
- Tmax ie. the time after administration of a drug when the maximum plasma cannabinoid concentration is reached
- the oral formulations of the present invention provide enhanced AUC and Cmax of the cannabinoids delivered in comparison both to lipid free formulations and/or to the LCT
- Formulations provided herein may optionally employ the formulation techniques, including micellar formulations, disclosed herein, and optionally with coatings specifically designed to place the capsules/tablets in a specific section of the GI tract before dissolution.
- the invention comprises a cannabinoid oil extract with a carrier oil selected from MCT oil, camelina oil and a marine oil, forming particles of 20-600 nm diameter (95% distribution) and encapsulated in a gel capsule (hardgel or softgel).
- a gel capsule hardgel or softgel
- such capsule is coated with delayed release coating.
- the delayed release coating is triggered to resist release in the acid conditions of the stomach and to provide enhanced release elsewhere in the gut such as the small intestine (pH 6), the terminal ileum (pH 7.4) or the caecum (pH 5.7).
- Figure 1 graphs the bioavailability of THC absorbed from the LCT formulation (12 mg/kg THC in sesame oil) reported by Zgair supra.
- Sesame oil is an LCT oil. It has high levels of Omega- 6 (co6) and low levels of Omega-3 (co3), corresponding to a: co3:co6 ratio of approximately 1 :50 (0.02).
- the ingredients will be formulated together for preparing the unit dosage form.
- the UDF is a pill, tablet, capsule, film, or wafer, any of which may optionally be orally disintegrating, or a lollipop, lozenge, oil, tincture, or syrup. The formulation process will be adjusted accordingly. Pills and tablets are prepared from solid formulations.
- Syrups, oils and tincture are liquid formulations.
- An orally disintegrating film, wafer, tablet or a lollipop or lozenge provides the UDF in an oral form wherein the active ingredients are at least partly absorbed directly in the buccal cavity.
- Capsules may be either solid formulations (e.g.
- Oil-based formulations used in soft- gels
- Oil based formulations with little or no water are typically easily encapsulated.
- Oil-in-water formulations may comprise microemulsions, liposomes, nanoemulsions, micelles, and other forms known in the art.
- Preferred capsule types are soft gelatin capsules (softgels) and hard gelatin capsules.
- Soft Gelatin Capsules softgels
- soft-gels are well known in the art.
- soft-gels are used for formulations not based on water, such as oil-based solutions, because water based solutions would dissolve the gelatin.
- the basic steps of softgel manufacturing are: Gelatin Preparation (the process of blending and heating granulated gelatin into a thick syrup for use in encapsulation); Fill Material Preparation (the process of preparing the non-aqueous oil or paste containing the lipid carrier and cannabinoid components that will be encapsulated); Encapsulation (the process of converting the gel mass into a thin layer of gelatin and wrapping it around the fill material to form a softgel); Drying (the process which removes excess moisture from the gelatin shell to shrink and firm up the softgel); the softgel could incorporate a Coating step (the process of coating the capsule with a coating designed to release the capsule within the digestive system); and finally Cleaning, Inspection and Sorting.
- Gelatin Preparation the process of blending and heating granulated gelatin into a thick syrup for use in encapsulation
- Fill Material Preparation the process of preparing the non-aqueous oil or paste containing the lipid carrier and cannabinoid components that will be encapsulated
- Hard gelatin capsules are made of two parts, the body and a cap. This form of capsule holds dry ingredients in the form of powders, granules or tiny pellets. They may also include cannabis oils of various viscosity, such as diluted cannabis oil and concentrated cannabis extracts.
- the body is first filled with the mix of active ingredients and any excipients used, and then closed with the cap using either a manual or automated or semi-automated capsule filling machine, such as those
- Delayed release to the gastrointestinal tract can be achieved for softgels or hard gels by enteric coatings which delay disintegration until after passing from stomach to the intestine; or by formulation techniques such as pellets which resist release until they pass into a specific intestinal domain. Such techniques are widely known in the art.
- enteric coatings which delay disintegration until after passing from stomach to the intestine; or by formulation techniques such as pellets which resist release until they pass into a specific intestinal domain.
- formulation techniques such as pellets which resist release until they pass into a specific intestinal domain.
- Such techniques are widely known in the art.
- An example is WIPO patent publication WO2017075215A1 to McGuffy and Bell, incorporated herein by reference in its entirety, for extended release film-coated softgel or hard-shell capsules.
- a wide variety of technologies are available for a buccal or sublingual formulation such as an orally disintegrating thin film, wafer or tablet, or a lollipop, and/or lozenge.
- Sublingual tablets, wafers, films and strips can be designed to rapidly disintegrate (5-15 seconds) providing rapid access to buccal cavity capillaries and avoid the hostile environment of the gastrointestinal track.
- Lollipops and lozenges provide a combination of buccal and gastric administration.
- the technologies are widely used with therapeutic agents where rapid onset is desired. (See Lamey and Lewis“Buccal and Sublingual Delivery of Drugs” Ch 2 in“Routes of Drug Administration” Ed. Florence and Salole (Butterworth- Heinemann).
- Orally disintegrating tablets (ODTs) of the invention can be based on solid lipid micro-pellets (SLMPs).
- SLMPs can be prepared using the hot melt extrusion technique and utilizing lipid carriers such as Compritol, Precirol and white beeswax either alone or in mixtures.
- lipid carriers such as Compritol, Precirol and white beeswax either alone or in mixtures.
- ODTs demonstrate sustained drug release and a taste masking effect.
- methods and compositions of the invention may associate the disclosed formulations with one or more signifiers permitting the consumer to determine the defined dose of selected cannabinoids therein.
- A“signifier” means a visual mark or symbol that the consumer recognizes as referring to a specific defined dose.
- the signifier chosen may have elements of meaning, such as a number and unit, (e.g.“5 mg” or“10 mg” or simply“5” or“10”) or it may be an abstract signifier, where its meaning, in terms of defined dose, can be determined by reference to a standard. The meaning may be determined directly by the consumer or indirectly via a device.
- the signifier may be associated directly with the formulation by such means as embossing, or by colour, pattern or shape feature.
- the signifier may be associated with the packaging.
- the packaging may include signifiers directly interpreted by consumers or signifiers which are machine readable codes. In all embodiments, the signifier allows the consumer to determine the defined dose of selected cannabinoids therein.
- the signifier may be associated directly with the UDF before, during or after encapsulation by such means as edible ink(s) imprinted on the surface of the capsule, or by embossing, by engraving (such as laser-engraving), or by color, pattern or shape feature.
- the edible ink applied to the capsule may include shellac from about 10% to about 30% by weight, about 20% to 70% by weight of at least one solvent, and at least one soluble or insoluble pigment from about 10% wt to about 40% wt.
- the shellac provides structure, enhances adherence to the printing plate and capsule, and/or act as a pigment carrier.
- An edible ink formulation may include 10% wt to about 30% wt shellac.
- the UDF is preferably provided in a sealed package, which functions as a barrier limiting moisture fluctuation, reducing oxidation, and enhancing shelf-life, etc.
- the packaging is optionally a gas-impermeable container having a hermetic closure which in the context of the present invention includes a blister pack.
- the UDFs may be individually sealed and packaged in blister packs.
- the blister packs may be designed to be child resistant and/or senior friendly in order to increase safety and convenience. While physically protecting the UDFs, the blister pack controls humidity and is impermeable to gas exchange thereby enhancing shelf life.
- the substantially gas exchange impermeable packaging examples include, but are not limited to, Al/Al blister, and Al-polychloro-3-fluoroethylene homopolymer/P VC laminate blister.
- the sealed package may be a re-sealable multi- package impermeable to gas exchange.
- UDFs of the invention may be expelled from production into the open blister cavities. Cavity depth and shape must be suitable for the unit.
- the open blister cavity is then sealed with a gas impermeable membrane to maintain quality of product and to reduce dehydration, rehydration or oxidation.
- the packaging may be performed in an inert gas atmosphere.
- the blister is packed in an inert gas atmosphere such as nitrogen gas comprising little or no oxygen.
- the final sealing step of the packaging method may be operated in the inert gas atmosphere in a gas enclosure protected from ambient air.
- Example 1 Use of lipid carriers to enhance cannabinoid bioavailabilitv.
- Oral formulations of the invention are tested to determine key pharmacokinetic (PK) parameters and to identify which lipid carriers provide enhanced exposure over time
- PK assays are used to identify plasma concentration over time, area under the curve (AUC) exposure over 24hrs, systemic clearance rate (CL) and systemic bioavailability. The combination is also tested against the individual components.
- the 24hr exposure identifies if the UDF should be administered QD (once a day) or BID (x 2 a day) or more often, or less often.
- Standard PK models are widely available and can be performed with a commercial service.
- a preferred method is to use at least 4 Male Sprague Dawley rats (210-230 g) who receive either an intravenous (i.v. 2, 5, 10 mg/kg) or oral (5, 10, 12, 20 and/or 30 mg/kg) dose of each compound separately, or combined in formulation.
- Blood, urine, cerebrospinal fluid (CSF) or other appropriate biological fluid is removed at periodic intervals.
- the biological fluid is tested for active compound(s) in order to construct concentration vs. time profiles. These data are analyzed and pharmacokinetic parameters are calculated in order to assess in vivo pharmacokinetic activity.
- the study uses a fixed dose of each component in the combination in a fixed vehicle formulation.
- PEG polyethylene-glycol
- components are prepared from a powder form, first in 5% ETOH, then with 40% PEG. The components are combined and topped up with distilled water to 100% volume. If components are not sufficiently soluble, PEG may be increased to 60% and also add 10% PG.
- Plasma and other tissue samples are tested for the administered cannabinoids and the lipid carrier administered to the animal.
- the samples are also tested for significant metabolites, some of which may have more potent effects than the parent administered compounds.
- the samples may also be used to determine baseline levels of serum biomarkers which are relevant to the
- Biomarkers of interest to the compositions of the invention include IL-6, NFkB, TNF alpha, C-reactive protein, and any other biomarker known to be or potentially implicated in the development of a disease or disorder.
- THC was prepared by Emerald Health Therapeutics (Victoria, BC) in ethanol-extracted cannabis concentrates diluted in each of a selection of carrier oils including: sesame oil (Sigma-Aldrich, SKU #S3547), krill oil (Grizzly Pet Products, SKU #B00VEZHL7K), camelina oil (Neptune Wellness Solutions, Product Code: RCAMO001) and camelina oil with LabrasolTM surfactant (Gattefosse, Product Code: 160865).
- the latter camelina oil and LabrasolTM surfactant formulation was prepared by slowly adding LabrasolTM to camelina oil heated to 60-70°C.
- THC was formulated to a dose of l2mg/kg in the carrier oil. The volume of administration is adjusted per individual animal’s body weight.
- Rats are orally administered one of the above formulations by oral gavage (volume up to 0.5ml) at time zero. 0.25ml blood was collected from the arterial catheter at 60, 180, 300, 480, 720 and 1440 minutes after drug treatment. Blood samples were promptly centrifuged to separate plasma, stored in duplicate and kept at -80°C until ready for analysis.
- FIG. 2 sets out observed results of the experiment.
- camelina oil provides a significant enhancement to bioavailability of THC taken orally. This effect is particularly enhanced when the camelina is formulated with a surfactant such that it becomes an emulsion upon administration to the aqueous gut environment.
- Krill oil also provides an enhanced bioavailability compared to sesame oil.
- Camelina oil and krill oil are examples of carrier oils having a relatively high ratio of Omega-3 to Omega-6 lipids of about 1.0 or greater. These observations lead the inventors to conclude that such formulations will provide significantly different physiological effects compared to THC products taken with Omega-3/Omega-6 ratios below 1.0.
- THC is provided in camelina oil, preferably mixed with surfactant, where with THC effects on the consumer are substantially enhanced compared to THC without a carrier oil or surfactant.
- Alternative preferred products include lower dose THC capsules (e.g. 4mg THC) which are provided in a carrier oil having a ratio of Omega-3 to Omega-6 lipids of about 1.0 or greater, such as a camelina oil emulsion, which due to enhanced bioavailability, have the effect of lOmg THC capsules provided without carrier oil, or with a long chain fatty acid carrier such as sesame oil which has a low ratio of Omega-3 to Omega-6 lipids of below 1.0.
- the invention can be described as a method to enhance the effect of THC to a consumer by providing it in a carrier oil having a high ratio of Omega-3 to Omega-6 lipids of about 1.0 or greater, and optionally with such oil in an oil carrier emulsion, most preferably where the carrier oil is camelina oil.
- a“high-impact THC capsule” where a lower dose THC capsule according to the invention has the physiological effect of a higher dose prior art capsule.
- the invention provides a physiological impact of about 2.5 times higher than a prior art dose of THC in a prior art formulation.
- compositions of the invention are tested in models corresponding to the disease and/or conditions proposed for use. These may be selected from among models of anxiety, pain, sleep induction, calmness induction, alertness induction, weight control, weight loss, obesity, diabetes and metabolic syndrome.
- successful treatment may be identified according to the behavioural results identified in the assay, or by measuring biomarkers of disease progression/treatment, such as IL-6, NFkB, TNF alpha, C-reactive protein, and any other biomarker known to be or potentially implicated in the development of the disease or disorder being studied.
- biomarkers of disease progression/treatment such as IL-6, NFkB, TNF alpha, C-reactive protein, and any other biomarker known to be or potentially implicated in the development of the disease or disorder being studied.
- Example 3 Unit Dosage Form (TJDF) Oral Capsule Embodiments
- Example 3-1 Island Mist Capsule (HardGel; Low-Dose; 250mg volume)
- Example 3-2 Island Mist Capsule (SoftGel; High-Dose CBD; 250mg volume)
- Example 3-3 TimeWarp A3 CAPSULE (Softgel; Low-Dose THC; 250mg volume)
- Example 3-4 Island Mist Capsule (HardGel; Low-Dose THC; Medium Dose CBD; 250mg volume)
- capsule shell and all carrier including capsule shell and all carrier, filler, stabilizer, and anti-oxidant, etc.
- compositions and methods described herein are illustrative and not intended to be limiting on the claims of the invention more particularly set out below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
Abstract
Described herein are cannabinoid formulations for oral administration. Further described herein are methods for orally administering one or more cannabinoids to a subject in need thereof.
Description
IMPROVED C ANNABIN OID BIO AVAILABILITY
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of United States Provisional Application No.
62/723,229, filed August 27, 2018, which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
[0001] Cannabinoid molecules, such as tetrahydrocannabinol (THC), cannabidiol (CBD) cannabigerol (CBG), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabinchromene (CBC), and cannabigerolic acid (CBGA), are known to cause a variety of therapeutic and psychotropic effects when administered to a subject.
[0002] Cannabinoids from the plant genus Cannabis could be considered a type of natural health product, but historically they have not been legally available. The laws which have criminalized possession or use of cannabis have been the primary restraint. These laws were put in place apparently to control the use of one specific cannabinoid, delta-9 tetrahydrocannabinol (THC), which causes a mild temporary psychotropic effect in users. But it is well known that dozens of other cannabinoids are also present in cannabis, none of which have psychotropic effects, and which have, or potentially may have, beneficial pharmacological effects in humans. These alternate cannabinoids which are devoid of psychotropic effect include but are not limited to tetrahydrocannabinolic acid (THCA), cannabinolic acid (CBNA), cannabidiolic acid (CBDA) and cannabigerolic acid (CBGA) and the de-carboxylated derivatives cannabinol (CBN), cannabidiol (CBD) and cannabigerol (CBG). With the de-criminalization of cannabis in some jurisdictions, the opportunity for use of cannabinoids in diverse health regimens is becoming possible.
[0003] Cannabinoids are key players in biological systems and bind to receptors in the body known as cannabinoid receptors which have been implicated in a variety of physiological functions, including appetite, pain, emotional behavior (mood), memory, and inflammation. There are currently two known well defined subtypes of cannabinoid receptors, called CB1 and CB2. The CB1 receptor (CB1R) is expressed mainly in the brain (central nervous system or "CNS"), and also in the lungs, liver and kidneys. The CB2 receptor (CB2R) is expressed mainly in the immune system and in hematopoietic or blood cells. There is mounting evidence that there are other novel cannabinoid receptors which are similar to CB1R and CB2R but which are unique.
[0004] In general, cannabinoid molecules have traditionally been administered via inhalation, for example by smoking or heating and inhaling the vapours of cannabis plants or cannabis extracts.
Oral administration of such molecules, as compared with administration via inhalation, can provide improved consistency of dosing, more discreet administration, and increased convenience for users.
SUMMARY OF THE INVENTION
[0005] Described herein are cannabinoid formulations for oral administration, providing consistency of dosing and discreet administration.
[0006] In one aspect, described herein are cannabinoid formulations for oral administration, and the oral administration thereof, the formulations comprising: one or more cannabinoids selected from the group consisting of: 0.1 100 mg tetrahydrocannabinol (THC); 0.1 750 mg
tetrahydrocannabinolic acid (THCA); 0.1 750 mg cannabidiol (CBD); 0.1 750 mg cannabidiolic acid (CBDA); 0.1 750 mg cannabigerol (CBG); 0.1 750 mg cannabinchromene; and a lipid carrier comprising one or more lipids selected from the group consisting of: camelina oil; a marine phospholipid; a krill oil; a fish oil; chia seed oil; flaxseed oil; an oil comprising an omeg-3 to omega-6 ratio of about 1.0 or higher, about 1.5 or higher, about 2.0 or higher, or about 2 2 or higher; a hydrolyzed oil; a vegetable oil; hemp oil; an oil containing medium-chain fatty acids (MCFAs); and an oil containing long-chain fatty acids (LCFAs). In some embodiments, the lipid carrier comprises or consists of camelina oil. In some embodiments, one or more of the one or more cannabinoids is dissolved and/or suspended in the lipid carrier. In some embodiments, the cannabinoid formulation is in a unit dosage form selected from a pill, tablet, capsule, film, wafer, lollipop, lozenge, oil, tincture, or syrup. In some embodiments, the cannabinoid formulation is an orally disintegrating pill, tablet, capsule, film, or wafer. In some embodiments, the cannabinoid formulation is a pill or tablet and further comprises an enteric coating for containing the one or more cannabinoids and the lipid carrier. In some embodiments, the cannabinoid formulation is a pill, tablet, or capsule and further comprises an outer shell that is substantially opaque to one or both of ultraviolet and visible light. In some embodiments, the cannabinoid formulation further comprises a further carrier oil. In some embodiments, the cannabinoid formulation further comprises a stabilizer. In some embodiments of the cannabinoid formulation, the lipid carrier is present in the form of an emulsion. In some embodiments of the cannabinoid formulation, the emulsion is a nanoemulsion.
[0007] In some embodiments of the cannabinoid formulation, upon administration of the cannabinoid formulation to a subject, a target bioavailability is achieved. In some embodiments, the formulation comprises a first unit dose amount of a dosed cannabinoid, further wherein the administration is by oral administration, and wherein the target bioavailability is a bioavailability of THC or a THC liver metabolite which is greater than a baseline bioavailability, the baseline bioavailability being that achievable from oral administration to the subject of a control
composition containing the first unit dose amount of the dosed cannabinoid in a carrier comprising at least 90%, or consisting of, sesame oil. In some embodiments, the dosed cannabinoid is THC and wherein the cannabinoid formulation comprises about 30-50% of the unit dose amount of THC in an emulsion. In some embodiments, the target bioavailability is a THC or THC liver metabolite bioavailability in the subject that is at least 140%, as measured by subject Cmax and/or subject AUC, of the baseline bioavailability. In some embodiments, the target bioavailability is a THC or THC liver metabolite bioavailability in the subject that is: (i) at least 108.5%, at least 146.9%, at least 159.6%, or at least 200%, as measured by subject Cmax, and/or (ii) at least 144.3%; at least 159.6%, at least 200%, or at least 252.1%, as measured by subject AUC, of the baseline bioavailability. In some embodiments, the target bioavailability is a bioavailability of: THC; 11- OH-THC; and/or THC-COOH.
[0008] In some embodiments of the cannabinoid formulation, one or more of the cannabinoids is in the form of an organic solvent-based extract of cannabis. In some embodiments of the cannabinoid formulation, at least one further cannabinoid selected from the group consisting of cannabigerolic acid (CBGA), tetrahydrocannabivarin(THCV). In some embodiments, the cannabinoid formulation comprises CBD in an amount between 10-50 mg. In some embodiments, the cannabinoid formulation comprises 25 mg CBD. In some embodiments, the cannabinoid formulation comprises 500 mg CBD. In some embodiments, the cannabinoid formulation comprises the cannabinoid is evenly dispersed within at least a portion of the unit dosage form. In some embodiments, the cannabinoid formulation comprises a signifier signifying a cannabinoid dosage is associated directly with the unit dosage form by embossing, or by colour, pattern, or shape feature. In some embodiments, the signifier is adapted to be directly interpreted by a consumer and/or is a machine- readable code. In some embodiments, the unit dosage form is contained in an individual blister pack sealed in an inert gas atmosphere comprising little or no oxygen. In some embodiments, the lipid carrier is present in the form of a nanoemulsion comprising lipid particles having an average particle size of about 20-100, 20-200, 20-300, 20-400, 20-500, 20-600, 100-300, 200-500, or 100- 600nm. In some embodiments, the lipid carrier comprises MCFAs comprising or consisting of 12- 16 carbon atoms or LCFAs comprising or consisting of 13 or more carbon atoms. In some embodiments, the cannabinoid formulation comprises an enteric coating for containing the one or more cannabinoids and the lipid carrier, wherein the enteric coating degrades, dissolves, or otherwise provides a release of the cannabinoid and the lipid carrier in an environment having a pH value of below about 5.5, at about 5.5 or greater, at about 6.0 to about 6.5, at about 6.5 to 7.5, or greater than about 7.5.
[0009] In one aspect, described herein is a method of administering one or more cannabinoids to a subject, comprising orally administering to the subject a formulation comprising one or more cannabinoids selected from the group consisting of: 0.1 - 100 mg tetrahydrocannabinol (THC); 0.1 - 750 mg tetrahydrocannabinolic acid (THC A); 0.1 - 750 mg cannabidiol (CBD); 0.1 - 750 mg cannabidiolic acid (CBD A); and 0.1 - 750 mg cannabigerol (CBG); 1 - 750 mg cannabinchromene (CBC); and a lipid carrier comprising one or more lipids selected from the group consisting of: camelina oil; a marine phospholipid; fish oil; krill oil; flaxseed oil; an oil comprising an omeg-3 to omega-6 ratio of about 1.0 or higher, about 1.5 or higher, about 2.0 or higher, or about 2.2. or higher; a hydrolyzed oil; a vegetable oil; hemp oil; an oil containing medium-chain fatty acids (MCFAs); and an oil containing long-chain fatty acids (LCFAs). In some embodiments, the lipid carrier comprises or consists of camelina oil. . Further described herein is a method of
administering a therapeutically and/or psychotropically effective amount of one or more cannabinoids to a subject, comprising orally administering to the subject a cannabinoid formulation as described herein.
[0010] In some embodiments, the subject has a disease or disorder treatable by the administration of the one or more cannabinoids. In some embodiments, the disease or disorder is selected from the group consisting of: pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes, metabolic syndrome, nausea (acute or anticipatory), epilepsy, spasticity, schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, bacterial and/or fungal infection, fibromyalgia, appetite enhancement, appetite suppression, and any combination thereof. In some embodiments, the disease or disorder is selected from the group consisting of: pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes, metabolic syndrome, nausea (acute or anticipatory), epilepsy, spasticity, schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, fibromyalgia, appetite enhancement, appetite suppression, and any combination thereof.
[0011] In some embodiments, the formulation for oral administration comprises a unit dose or combination dose of cannabinoid(s) selected from the list consisting of (each cannabinoid milligram amount about or equal to):
• 25mg THCA and 2mg THC;
• 25mg THC;
• lmg THCA, 25mg CBD A, and 2mg CBD;
• lm
• g THCA and 25mg CBD;
• 25mg THCA, 2mg THC, 25mg CBDA, and 2mg CBD;
• 25mg THCA, 2mg THC, and 2mg CBD;
• 25mg THC and 25mg CBD;
• 25mg THC and 2mg CBD;
• lmg THC, 25mg CBD; 25mg CBG, and 25mg CBC;
• 25mg THC and 25mg THCV;
• 9mg THCA and lmg THC;
• lOmg THC;
• 9mg THCA, lmg THC, 9mg CBDA, and lmg CBD;
• 9mg THCA, lmg THC, and lOmg CBD;
• lOmg THC and lmg CBD;
• 1 Omg THC and 1 Omg THCV;
• 600mg THC;
• 600mg THCA and 50mg THC;
• lOOmg THC;
• 600mg CBDA;
• 25mg THCA, 600mg CBDA, and 60mg CBD;
• lOOmg CBD;
• 4mg THC and lOOmg CBD;
• 600mg CBD;
• 25mg THC and 600mg CBD;
• 600mg CBG;
• 3 OOmg THCA and 3 OOmg CBDA;
• 3 OOmg THCA, 30mg THC, 300mg CBDA, and 30mg CBD;
• 3 OOmg THCA and 30mg CBD;
• 3 OOmg THCA, 3 Omg THC, and 3 OOmg CBD;
• lOOmg THC and lOOmg CBD;
• lOOmg THC and 30mg CBD;
• 3 OOmg THC and 3 OOmg CBG;
• 3 OOmg THC and 300mg CBC;
• 3 OOmg CBD and 3 OOmg CBG;
• 3 OOmg CBD and 300mg CBC;
• 3 OOmg CBD, 300mg CBG, and 300mg CBC;
• lOmg THC, 250mg CBD, 250mg CBG, and 250mg CBC;
• lOOmg THC and 500mg THCV;
• 300mg CBD and 300mg THCV; and
• 1 OOmg CBD and 1 OOmg THCV.
INCORPORATION BY REFERENCE
[0012] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] The novel features of the invention are set forth with particularity in the appended claims.
A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
Figure 1 : Plasma concentration-time profiles of A9-tetrahydrocannabinol (THC) following IV bolus (4mg/kg, n=5), oral lipid-free formulation (12 mg/kg, n=6, and oral long-chain triglyceride (LCT)-based formulation (12 mg/kg, n=5) to rats. The data are shown as mean +/- S.E.M. Data taken from Zgair et al. Am J Transl Res
20l6;8(8):3448-3459.
Figure 2: Plasma concentration-time profile of THC following oral gavage of THC (12 mg/kg) formulated with four different carrier oils (sesame, krill, camelina and emulsified camelina oil). Data is shown as mean +/- S.E.M.
Figure 3: Plasma concentration-time profile of 11 -OH- THC following oral gavage of THC (12 mg/kg) formulated with four different carrier oils (sesame, krill, camelina and emulsified camelina oil). Data is shown as mean +/- S.E.M.
Figure 4: Plasma concentration-time profile of THC-COOH following oral gavage of THC (12 mg/kg) formulated with four different carrier oils (sesame, krill, camelina and emulsified camelina oil). Data is shown as mean +/- S.E.M.
DETAILED DESCRIPTION OF THE INVENTION
[0014] The potential to use cannabinoids and carrier oils in combination has yet to be fully explored. The invention herein is directed to novel combinations comprising A) one or more carrier oils, and B) one or more cannabinoids, in oral formulation. Such products are useful as health products, dietary supplements, and for treatment of human diseases and disorders.
[0015] The invention herein provides novel oral formulations comprising a combination of one or more cannabinoids with one or more lipid carriers. The invention has a variety of advantages, including a surprising increase in cannabinoid bioavailability for the treatment of human diseases and disorders. In particular, the oral formulation combinations provided herein demonstrate increased bioavailability of cannabinoids for the treatment of pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes and metabolic syndrome, acute and anticipatory nausea, epilepsy, spasticity,
schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, bacterial and/or fungal infection, fibromyalgia, appetite suppression, and/or to act as an anti -proliferative agent.
Definitions
[0016] “Bioavailability” refers to the fraction or dose of an administered substance capable of being absorbed by the body’s circulatory system and available for use or storage by a body (e.g., a cannabinoid). Bioavailability may be measured by calculating the concentration of a substance administered to a body over time. Cmax is a term used in pharmacokinetics refers to the maximum concentration that a compound/drug achieves in tested area after the drug has been administrated. The Cmax is often measured in an effort to show bioequivalence between a generic and innovator drug product. AUC (area under the curve) represents the total drug/compound exposure across time. AUC is proportional to the total amount of a compound absorbed by the body for a dose of a compound
[0017]“ Cannabinoid” refers to a chemical compound that is capable of acting on cannabinoid receptors, for example in the brain. Cannabinoids may be produced naturally in the body
(endocannabinoids), found in cannabis and some other plants (phytocannabinoids), or
manufactured artificially (synthetic cannabinoids). Cannabinoids produced by cannabis during its cultivation and growth include tetrahydrocannabinolic acid (THCA), cannabinolic acid (CBNA), cannabidiolic acid (CBDA), cannabichromenic acid (CBCA), and cannabigerolic acid (CBGA).
As used herein, cannabinoid may also refer to the corresponding decarboxyl ated moieties, tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabinchromene (CBC) and cannabigerol (CBG), (each of which may be derived from its parent compound by mild heating
typically above l05°C), and the corresponding liver metabolites that result upon oral consumption by humans of these compounds, such as but not limited to 1 l-OH-THC and THC-COOH (also known as 1 l-Nor-9-carboxyTHC). Cannabinoids may be synthesized by chemical or biological methods. Phytocannabinoids may be distinguished from endocannabinoids which are chemically distinct, are synthesized in mammalian cells from lipids and other macromolecule precursors, which are not phytocannabinoids, and which may be endogenous ligands of the CB1 and/or CB2 receptors.
[0018] “ Cannabis” as used herein includes all members of the Cannabis genus, including without limitation Cannabis sativa, Cannabis indica, Cannabis ruderalis, and hybrids thereof.“Cannabis” also includes Charlotte’s Web and other high CBD, low THCA plant varieties.
[0019]“Defined dose” means a dose of one or more active ingredients (typically cannabinoids) which has been selected during the production process and may be signified to a consumer by a signifier associated with the object.
[0020]“Effective dose” may refer to the amount of a cannabinoid substance sufficient to induce a change in an individual user. An effective dose may also mean an amount of a cannabinoid substance that is needed to provide a desired level of said cannabinoid in the bloodstream of an individual user to provide a desired response. An effective dose can be administered in one administration, or through multiple administrations of an amount that total an effective dose. The effective dose may be the result of empirical and/or individualized (case-by-case) determination on the part of an individual user.
[0021]“Enteric coating” refers to a barrier applied to an orally delivered substance that prevents or delays its dissolution or disintegration in the gastric environment. Enteric coatings can protect an orally delivered substance from the acidity of the stomach, protect the stomach from detrimental effects of an orally delivered substance, or delay the release of an orally delivered substance until after the stomach (ex. intestinal tract). Examples of enteric-coated dosage forms include without limitation tablets, mini-tablets, pellets, granules, capsules, gel capsules.
[0022]“Emulsion” refers to a mixture of two or more immiscible liquids in which one is present as droplets distributed throughout the other. The average droplet size in an emulsion may be between 100-1000 nm.
[0023]“Fatty acid” refers to a carboxylic acid with an aliphatic chain, which may be either saturated or unsaturated. The aliphatic chain may be short, medium, or long depending on the number of carbon atoms. For example, short chain fatty acids may comprise five or fewer carbon atoms, medium chain fatty acids may comprise 6-12 carbon atoms, and long chain fatty acids may comprise 13 or more carbon atoms.
[0024]“Lipid carrier” refers to lipid-based drug delivery systems including without limitation emulsions, nanoemulsions, lipid nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers. Lipid carriers can be used to increase solubilization and absorption of hydrophobic compounds, which may result in enhanced bioavailability. Suitable lipids for use in formulating lipid carriers of the invention include, without limitation, camelina oil, marine phospholipids.
[0025]“Liposome” means a vesicle, which may be spherical, having at least one lipid bilayer. Liposomes can be used as a vehicle for delivery of nutrients and/or pharmaceutical agents.
[0026]“Micelle” means an aggregate (or supramolecular assembly) of surfactant molecules dispersed in a liquid colloid.
[0027]“Nanoemulsion” refers to a mixture of two or more immiscible liquids in which one is present as nano-sized microscopic droplets distributed throughout the other. The average droplet size in a nanoemulsion is usually between 20-600 nm.
[0028]“ Oral Formulation” means a formulation which is conveniently administered orally to a human subject.
[0029]“Pharmacodynamic” parameters (PD) means dose-response relationships, that is, the relationships between a substances’ plasma concentration and its effect.
[0030]“Pharmacokinetic” (PK) parameters are usually used to describe the rate of absorption of a substance into a biological system. Graphing a substance’s serum concentration versus time reveals the drug’s basic PK properties: the maximum concentration the drug attains (Cmax), the time at which maximum concentration occurs (tmax), and the area under the concentration-versus-time curve (AUC) which estimates total systemic exposure.
[0031]“Psychotropic dose” means a dose of a substance capable of affecting a user’s mental state. Examples of psychotropic cannabinoids include without limitation THC, cannabinol (CBN).
[0032]“Unit dosage form” or“UDF” means a physically fixed unit dose of a formulation which is conveniently consumed by a consumer in unit form (e.g. requires no measuring or adjusting of dosage before consumption). A consumer may consume one or more UDFs at a time.
Ingredients of the Unit Dosage Form
[0033] The unit dosage forms of the invention may comprise a lipid carrier, which may be formulated from one or more lipids including, without limitation, camelina oil and/or a marine phospholipid.
[0034] Camelina oil is an edible oil derived from the seeds of Camelina sativa. Camelina oil has been found to contain high amounts of omega - 3 fatty acids and vitamin E, making it suitable for use as a nutritional supplement and as a general purpose oil. Due to its high vitamin E content,
Camelina oil may be used as an antioxidant and as an anti-inflammatory. Camelina oil may also be prepared as an extract of a cultivated Camelina sativa plant crop.
[0035] Phospholipid extracts derived from natural marine or aquatic sources have been shown to possess a variety of nutraceutical and/or therapeutic properties. These marine extracts may comprise a variety of phospholipids, fatty acid, metals, and flavonoid compounds. Examples of suitable marine phospholipids for use in formulating the lipid carriers of the present invention are further described in U.S. patent nos. 8,680,080 B2, 8,383,675 B2, and 8,278,351 B2 and others in the name of Neptune Tech and Bioresources Inc., all of which are incorporated herein by reference in their entirety.
[0036] The unit dosage forms of the invention may further comprise a defined dose of one or more cannabinoids selected from among the group consisting of:
0.1 - 750 mg tetrahydrocannabinolic acid (THCA),
0.1 - 100 mg tetrahydrocannabinol (THC),
0.1 - 750 mg cannabidiolic acid (CBDA),
0.1 - 750 mg cannabidiol (CBD); and
0.1 - 750 mg cannabigerol (CBG),
[0037] The cannabinoid(s) may be prepared as an extract of a cultivated cannabis plant crop (as described further below), or they may be synthetically prepared in a chemical process (as for example in patent applications WO2014134281, W02015068052, W02016030828 and others in the name of Full Spectrum Laboratories Limited (Dublin IE)), all of which are incorporated by reference in their entireties. When prepared as an extract, the composition may also comprise terpenes and other organic molecules co-extracted in the process.
[0038] As will be described further below, the unit dosage forms may also comprise diverse additional features which may include an anti -oxidant, other pharmaceutically acceptable additives, a carrier oil, an outer shell that is substantially opaque to one or both of ultraviolet and visible light, an enteric-coating, and/or a signifier which signifies the cannabinoid dosage of the unit dosage form, such as a signifier generated by embossing, or by colour, pattern or shape feature, which signifier may be adapted to be directly interpreted by a consumer and/or is a machine-readable code.
Preferred Combinations
In some embodiments, the formulation consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA,
CBD, CBC, and CBG, combined with a specific carrier oil, a particular lipid particle size, and a specific coating.
[0039] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0040] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0041] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0042] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0043] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 100 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0044] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0045] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A,
CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0046] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0047] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0048] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 200 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0049] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0050] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0051] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0052] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 300 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0053] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0054] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0055] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0056] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0057] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0058] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of
between 20 to 400 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0059] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
[0060] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
[0061] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
[0062] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
[0063] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 500 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5
[0064] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA, CBD, CBC, and CBG with camelina oil in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0065] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBDA,
CBD, CBC, and CBG with fish oil in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0066] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with krill oil in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0067] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with a medium chain fatty acid in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
[0068] In some embodiments the product consists of one or more cannabinoids, which in preferred embodiments comprise one or more members of the group consisting of THCA, THC, CBD A, CBD, CBC, and CBG with long chain fatty acid in a nanoemulsion with an average particle size of between 20 to 600 nm in a capsule or tablet with an enteric coating with a controlled release at pH values above 5.
Therapeutic Use of Unit Dosage Forms of the Invention
[0069] The oral formulations of the present invention may be used for the treatment or amelioration in humans and other animals of a range of diseases and conditions. The inventors have identified the advantages of the proposed novel combinations based on a variety of technical assessments which demonstrate surprising effects of the oral combinations on cannabinoid bioavailability relevant to the treatment or amelioration of a range of diseases and conditions. These assessments, described below, include 1) Identifying improved bioavailability and enhanced PK/PD of the combinations in in vivo models; and 2) By providing animal (including human) testing in complex diseases and disorders and models of complex diseases and disorders.
Therapeutic Effects of Cannabinoids
[0070] The therapeutic effects of cannabinoids are becoming increasingly well known.
Cannabinoids such as THC, CBD, CBG, and CBN interact with the body in different ways, leading
to a variety of cannabinoid-associated effects. For example, ingestion of THC may lead to increased relaxation or stress reduction, enhanced feelings of well-being and euphoria. THC has been used to treat ailments such as neuropathic pain, multiple sclerosis, Crohn’s disease, in cancer patients to increase appetite and reduce nausea, inflammation (swelling and redness), and muscle control problems. CBD has been shown to alleviate certain adverse effects of THC experienced by some consumers. CBD can act as a sedative, anti -convulsive, anti-inflammatory, anti-oxidant, or anti-depressant. CBG is an adrenergic, serotonergic, enzyme modulator, slow the proliferation of cancer cells, reduces intraocular eye pressure caused by glaucoma, inflammatory bowel disease, Crohn’s disease and analgesic, while CBN may regulate the immune system and induce sleep.
CBC is a non-psychoactive cannabinoid widely considered to interact with the endocannabinoid system (ECS) through stimulation of the body’s naturally occurring endocannabinoids, anandamide and 2-AG, and is a known agonist to TRPV1 and TRPA1 receptors (A. A. Izzo et al.: Br. J.
Pharmacol. 166, 1444 (2012)). Additionally, CBC is thought to be a selective CB2 receptor agonist which may have therapeutic implications for the treatment of pain and inflammatory conditions through CB2-mediated regulatory pathways (M. Udoh et al.: Br. J. Pharmacol. (2019).
Furthermore, CBC co-administered with THC produced an enhanced anti-inflammatory effect, suggesting a potential pharmacokinetic interaction between the two molecules (G. T. DeLong et al.: Drug Alcohol Depend. 112, 126 (2010). CBC has been identified as a molecule of interest for various therapeutic applications including pain, inflammation, digestive and gastrointestinal disorders. Furthermore, it is known to have antibacterial and antifungal effects, and could potentially contribute to the regeneration of brain cells, which possibly has implications in the treatments of multiple sclerosis bacterial and/or fungal infection,, fibromyalgia, dementia,
Alzheimer’s and other neurodegenerative related conditions.
[0071] Unit dosage forms of the present invention may be applicable to a wide range of diseases or conditions, including without limitation, inflammatory, immune, neurological, psychiatric disorders, seizures/epilepsy, anxiety and stress disorders, malignancies, metabolic disorders, nutritional deficiencies, infectious diseases, types of gastrointestinal disorders, sleep disorders, cardiovascular disorders, complex chronic diseases, and various types of pain, including chronic and neuropathic pain.
[0072] More particularly, unit dosage forms of the present invention may be applicable, although not only, to at least one of pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes and metabolic syndrome, acute and anticipatory nausea, epilepsy, spasticity, schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, bacterial and/or fungal infection, fibromyalgia, all the foregoing in
acute and/or chronic presentation, and may be further used to induce appetite suppression and/or act as an anti -proliferative agent.
Dose Selection
[0073] Compositions and methods of the invention feature a combination of lipid carrier(s) and one or more cannabinoids.
[0074] The combinations of the invention may comprise one or more cannabinoids selected from among the group consisting of:
0.1 - 750 mg tetrahydrocannabinolic acid (THCA),
0.1 - 100 mg tetrahydrocannabinol (THC),
0.1 - 750 mg cannabidiolic acid (CBDA),
0.1 - 750 mg cannabidiol (CBD);
0.1 - 750 mg cannabinchromene (CBC), and
0.1 - 750 mg cannabigerol (CBG).
[0075] In some embodiments, the oral combinations may comprise a defined dose selected from the following ranges (which may be referred to as“low dose”): about 0 mg, 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between 0 mg and 100 mg THC, about 0 mg, 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between Omg and 100 mg THCA, about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6,
7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or about any 1 mg interval between 0 mg and 100 mg CBD, and/or about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or about any lmg interval between 0 mg and 100 mg CBDA, or 10 mg, 20 mg, 3 Omg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or about any lmg interval between 0 mg and 100 mg CBG, and/or about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or about any lmg interval between 0 mg and 100 mg CBC. In some embodiments, the oral combinations comprise about 0 mg, 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or about any 1 mg interval between 0 mg and 100 mg of one of the foregoing compounds. In some embodiments, the oral combinations of the present invention have defined dosages for more than one of the foregoing compounds. For example, in some embodiments, the oral combinations comprise from about 0 mg - 1 mg, or any 0.1 mg interval therebetween THC,
about 0 mg, about 9 mg, about 90 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between 0 mg and 100 mg, about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between 0 mg and 100 mg CBD, and/or about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4,
5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between 0 mg and 100 mg CBDA. In some embodiments, the oral combinations comprise from about 0 mg, about 9 mg, about 90 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between 0 mg and 100 mg THC, 0 mg - 1 mg THCA, or any 0.1 mg interval therebetween, about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between Omg and 100 mg CBD, and about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5,
6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between 0 mg and 100 mg CBDA. In some embodiments, the compositions are substantially free of THC-type cannabinoid compounds. For example, in some embodiments the oral combinations comprise from about 0 mg - 1 mg, or any 0.1 mg interval therebetween THC, 0 mg - 1 mg THCA, or any 0.1 mg interval therebetween, about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between Omg and 100 mg CBD, and about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any lmg interval between Omg and 100 mg CBDA.
[0076] In some embodiments, the oral combinations may comprise a defined dose selected from the following ranges (which may be referred to as“high dose”): about 10 mg, 15, 20, 25, 30, 40,
50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about any 10 mg interval between 0 mg and 750 mg THCA, about 0 mg, 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between 0 mg and 100 mg THC, about 10 mg, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about any lOmg interval between Omg and 750 mg CBD, and/or about 10 mg, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about any 10 mg interval between 0 mg and 750 mg CBDA, or about 10 mg, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about any 10 mg
interval between 0 mg and 750 mg CBG, and/or about 10 mg, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about any 10 mg interval between 0 mg and 750 mg CBC. In some“high dose” embodiments, the oral combinations comprise about 10 mg, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about 10 mg interval between 0 mg and 750 mg of one of the foregoing compounds. In some“high dose” embodiments, the oral combinations of the present invention have defined dosages of more than one of the cannabinoids. In some high dose embodiments, the compositions are substantially free of THC-type cannabinoid compounds. For example, in some embodiments the oral combinations comprise from about 0 mg - 1 mg, or any 0.1 mg interval therebetween THC, 0 mg - 1 mg THCA, or any 0.1 mg interval therebetween, plus CBD in the amount of about 0 mg, about 25 mg, about 75 mg, about 10 mg, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about 10 mg interval between 0 mg and 750 mg, and/or CBDA in the amount of about 0 mg, about 25 mg, about 75 mg, about 10 mg, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg.
[0077] In some embodiments, the oral combinations described herein comprise an“effective” amount of one or more of the cannabinoid ingredients described herein. The term“effective amount” refers to an amount of the one or more cannabinoid ingredients sufficient to induce a response in an individual user, either subjectively or objectively determined. An effective amount also means an amount of the one or more cannabinoid ingredients that is needed to provide a desired level of cannabinoid(s) in the bloodstream of an individual user to provide an anticipated physiological response. An effective amount of a cannabinoid ingredient can be administered in one administration, or through multiple administrations of an amount that totals an effective amount, preferably within a 24-hour period. It is understood that the effective amount can be the result of empirical and/or individualized (case-by-case) determination on the part of the individual user. For example, a therapeutically effective amount of said one or more cannabinoid ingredients may be in the range of about 1 mg to 2,000 mg, or any 1 mg or 10 mg interval there between total cannabinoids per day.
[0078] In some low dose embodiments, an effective amount of one or more cannabinoid ingredients may be in the range of about 1 mg - 5 mg, or any 1 mg or 0.1 mg interval therebetween per day. For example, for an adult, about 1-2 mg, or 0.1 mg interval therebetween, a day total cannabinoids may provide a very low-end dose below the psychoactive threshold.
In some embodiments, an effective amount of THC may be in the range of about 5 mg - 25 mg, or any 1 mg interval therebetween. For example, most vapers inhale about 10 to 30 mg of THC to
establish a mild, temporary, psychoactive effect. In a high dose embodiment the oral formulation may contain THC in an amount of 25 mg to 100 mg.
[0079] In some embodiments, a composition of the present invention may comprise THCA in an amount between 5-200 mg, THC in an amount less than 1.0 mg, and CBDA in an amount between 0.1-600 mg, and have a total mass of 100-750 mg.
[0080] In some embodiments, a composition of the present invention may comprise THCA in an amount less than 5.0 mg, THC in an amount between 5-30 mg, and CBD in an amount between 0.1-600 mg, and have a total mass of 100-750 mg.
[0081] In some embodiments, a composition of the present invention may comprise THCA in an amount less than 1.0 mg, THC in an amount less than 1.0 mg, and CBD in an amount between 5- 600 mg, and have a total mass of 100-750 mg.
[0082] In some embodiments, a composition of the present invention may comprise THCA in an amount less than 1.0 mg, THC in an amount less than 1.0 mg, and CBG in an amount between 5- 600 mg, and have a total mass of 100-750 mg.
[0083] In some embodiments, an effective amount of CBD for treating conditions or disorders disclosed elsewhere herein may be in the low dose range of about 0 mg, about 7 mg, about 75 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between 0 mg and 100 mg per day. Preferably, the low dose amount of CBD may be about 50 mg per day. For example, a recommended CBD dosage standard may be about 25 mg of CBD taken twice a day.
[0084] Alternatively, in some embodiments, an effective amount of CBD for treating conditions or disorders disclosed elsewhere herein may be in the high dose range of about 50-2000 mg/day or higher. Such effective amounts may be provided by ingestion of multiple oral dosage forms comprising CBD in the amount of, about 50 mg, about 75 mg, about 100 mg, 200 mg, 250 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 750 mg, or any about any 10 mg interval between 100 mg and 750 mg.
[0085] In some embodiments, an effective amount of THCA may be in the range of about 0 mg, about 9 mg, about 90 mg, about 1 mg, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any about any 1 mg interval between 0 mg and 100 mg.
In some embodiments, only one cannabinoid will be present at a physiologically relevant level, in other embodiments two or more cannabinoids may be present at physiologically relevant levels.
The second cannabinoid may be one previously cited, or may be an alternative cannabinoid which may also be isolated from or extracted from cannabis, or may be a simple chemical derivative thereof.
[0086] Tables 1A-1C provide examples for preferred embodiments.
[0087] Table 1B - 250 mg capsule (low dose; lOmg THC maximum)
[0088] Table 1C - 1000 mg capsule (high dose)
[0089] The precise amount of cannabinoid required for an effective dose in an individual will depend upon numerous factors, e.g. type of cannabinoid(s) and type or combination of lipid carrier(s), type of lipid carrier, and the effect of the lipid carrier-cannabinoid combination on bioavailability. This disclosure provides UDFs suitable to obtain an effective dose which can be determined subjectively by the user or objectively by methods known to those skilled in the art.
An achievement of the invention is that by using the UDFs of the invention, users and medical advisors for the first time have knowledge of and certainty with the preferred doses of cannabinoid they are employing with the lipid carrier. This is preferably achieved with a signifier identifying dosage of one or more components, as detailed further below.
Source and quality of Cannabinoid
[0090] The cannabinoid(s) for use in the present UDFs may be prepared by a variety of methods. It may be provided in the original plant form, preferably dried and cured into a flowable powder suitable for encapsulating. An alternative preferred method is by extraction from a cultivated cannabis crop. Organic extraction is a preferred method, although aqueous extraction, typically employed to prepare hashish, is also possible. Organic extraction can be performed with a wide variety of organic solvents or super-critical carbon dioxide, and at a variety of temperatures and under a variety of conditions. (Fairbairn and Liebmann (1973) J. Pharm. Pharmac. 25: 150-155; Romano and Hazekamp (2013) Cannabinoids. l(l)-l-l l; Rovetto and Aieta (2017). J. Supercritical Fluids. 129: 16-27.), all of which are incorporated herein in their entireties. The resulting organic solvent-based extract can be, at room temperature, a liquid oil, or solid form wax, budder, or shatter depending on the conditions employed (which significantly impact the other plant alkyloids and polymers extracted by the process). Historically, less than 50% of cannabinoids were extracted from dried plant material. Fairbairn and Liebmann (1973), incorporated herein in its entirety.
Modem techniques may extract over 90%.
[0091] The unpredictability of cultivated cannabis provides another potential challenge to formulation of the disclosed UDFs. As is well known, the most common varieties C. sativa , C. indica and C. ruderalis , have distinct (but overlapping) ranges of cannabinoids. Varieties and strains which are crossed or hybridized generate further different cannabinoid ratios. And, the cannabinoid ratios and overall amounts within a single variety are strongly influenced by the conditions of cultivation, especially light cycle, temperature, soil condition, nutrient availability, timing of harvest and pathogen exposure. The result is that a cultivated cannabis plant can have, by dry weight, anywhere from 0% up to greater than 30% of selected cannabinoids, and the ratios between individual cannabinoids can be highly diverse.
[0092] Preferred cannabis sp. cultivars for use preparing cannabinoid extracts include: Acapulco Gold; Afghani; African; Cambodian red; Columbian; Hawaiian; Jamaican gold; Mexican red;
Panama red; Thai stick; Amnesia; AK-47; Amnesia Haze; Blueberry; Blue Dream; Bubba Kush; Bubblegum; Critical Mass; Durban Poison; Gorilla Glue; Haze; Hindu Kush; Jack Herer; Maui
Waui; Northern Lights; OG Kush; Purple Haze; and Skunk. Preferred for cultivation in Canada are: Altair, Angie, CS, Carmagnola, Carmen, Deni, ESTA-l, FINOLA, Fasamo, Fedrina 74, Felina 34, Fibranova, Fibriko, Fibrimon 24, Fibrimon 56, Georgina, GranMa, Grandi, Judy, Katani, Kompolti, Kompolti Hibrid TC, Kompolti Sargaszaru, Laura Secord, Lovrin 110, Martha, Petera, Picolo, Quida, UC-RGM, Uniko B, Victoria, and Yvonne.
[0093] Preferred cannabis sp. cultivars for use in preparing CBD extracts that contain little or no THC or THCA include: Charlotte’s Web and cultivars approved in Canada including CFX-l, CFX- 2, CRS-l, Canda, Crag, Joey, USO 14, USO 31, X-59 (Hemp Nut), Delores, Silesia, Alyssa, Zolotonosha 11, Anka, Jutta, CanMa, and Ferimon.
[0094] Another critical aspect of the cannabinoid preparation is that during the cultivation phase, cannabis naturally synthesizes tetrahydrocannabinolic acid (THCA) and cannabidiolic acid
(CBD A). These compounds convert respectively to THC (the primary psychoactive cannabinoid), and CBD (the non-psychoactive analgesic and anti-inflammatory cannabinoid) via decarboxylation. Decarboxylation may be induced by heating over l05°C and/or by exposure to ultraviolet (UV) light. Importantly, gastric acids do not decarboxylate THCA or CBD A. (See Wang et al. (2016) Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry. Cannabis Cannabinoid Res.; 1(1): 262-271.) Therefore, a critical aspect of extracted cannabinoids is quality control on whether the harvested crop has been subjected to decarboxylating conditions that would
decarboxylate THCA and CBDA to THC and CBD, respectively.
[0095] Because of the unpredictability of cannabis cultivation, preferably, extract preparations of cannabinoid(s) for use in UDFs of the present disclosure are analyzed to determine the precise concentrations of relevant cannabinoids, especially THCA, THC, CBDA and CBD, for use in preparing unit dosage forms of the invention.
As described above, the cannabinoids in the oral formulation of the present invention may be provided as dried plant matter, as extracts of plant matter, or as generated by chemical synthesis. A valuable parameter for usefulness is on whether the format is flowable. The cannabinoid format is preferably efficient for mixing with other components and for loading into capsules, forming tablets, and the like. Stickiness of powders or high -viscosity of liquids can be a deterrent to efficient preparation. The invention therefore takes advantage cannabinoid formats that are sufficiently flowable for use in manufacturing the UDFs described herein. Flowability of dried plant material may be enhanced by appropriate grinding and by addition of excipients, including but not limited to those described herein. Flowability of oil extracts may be enhanced by diluents, gliders and the like. Oil extracts with hydrophobic components may be mixed with powders to
provide a dry flowable powder which can easily be mixed with other UDF components (e.g., US Pat App. Publications 20170232210 and 20160243177). Alternatively, oil extracts may be spray dried with flowable particles to create a flowable powder format. In one preferred embodiment, extracts may be used to produce crystallized pure cannabinoids. Crystallized CBD can be prepared by high-vacuum treatment of extracts, as exemplified at
https://www.leafscience.eom/20l7/l l/06/cbd-isolate-powder/ (viewed 22-August-20l8).
Crystallized forms can be rendered into a suitable flowable powder by techniques common in the capsule/tablet industry.
Carrier Oils
[0096] It should be appreciated that the oral formulations of the present invention may comprise at least one carrier oil. This feature is particularly advantageous as the carrier oil(s) may increase the bioavailability of one or more cannabinoid ingredients.
[0097] A wide variety of carrier oils may be employed to dissolve, solubilize or otherwise formulate the components of UDFs of the present disclosure into a liquid or semi-solid formulation suitable for manufacturing the oral formulation and unit dosage forms of the invention. Carrier oils may comprise short chain, medium chain and/or long chain fatty acids. Typically, carrier oils comprise, by mass, from about 50% to about 98%, about 75% to about 95%, and preferably about 90% to about 93% of the liquid fill of the UDF. The oils may be formulated with the cannabinoid(s) and the other components of the invention through any known formulation process, including but not limited to surfactant mixtures, emulsions, liposomes (e.g. fully encapsulated or lipid- aggregated), and nanoparticles.
[0098] Carrier oil(s) for use in the presently disclosed formulations may be plant-based or animal- based. Plant-based carrier oils can be derived from the fatty portions of a plant, for example, from the seeds, kernels or nuts. Animal-based carrier oils can be derived from raw animal fat or from the fatty tissues of an animal, for example, the liver.
[0099] A carrier oil of the present invention may exist in a variety of forms. For example, a carrier oil may be an oil, fat, wax, or similar product, for example, lecithin. A carrier oil may be hydrolyzed, hydrogenated, or non-hydrogenated. A hydrolyzed carrier oil refers to a carrier oil that has been split into its component parts in the presence of an aqueous base. Examples of component parts of a carrier oil may include glycerol, fatty acids etc. A hydrogenated carrier oil refers to an oil with saturated fatty acids that may be solid at room temperature. A non-hydrogenated carrier oil refers to an oil with unsaturated fatty acids that may be a liquid at room temperature. A non-
hydrogenated carrier oil with unsaturated fatty acids can be chemically changed through the addition of hydrogen to form a hydrogenated carrier oil with saturated fatty acids.
[0100] In some embodiments, the carrier may be a bioactive or nutraceutical agent. Nutraceutical agents are natural, bioactive chemical compounds that have health promoting, disease preventing or medicinal properties
[0101] In some embodiments, oral formulations may comprise one carrier oil. In some
embodiments, oral formulations may comprise a mixture of at least two carrier oils. A mixture of carrier oils may comprise plant-based oils, animal-based oils, or a combination thereof.
In some embodiments, one or more carrier oils may be plant-based. Examples of plant-based carrier oils include without limitation almond oil, apricot kernel oil, avocado oil, borage seed oil, castor oil, chia seed oil, cranberry seed oil, corn oil, coconut oil, hazelnut oil, hemp oil, evening primrose oil, grapeseed oil, jojoba oil, linseed oil, macadamia nut oil, mustard seed oil, sesame oil, olive oil, cotton oil, peanut oil, pecan oil, pomegranate seed oil, poppy seed oil, rosehip oil, soybean oil, sunflower oil, and watermelon seed oil.
[0102] In some embodiments, one or more plant-based carrier oils may be an essential oil or volatile oil such as bay oil, bergamot oil, balm oil, cedarwood oil, cherry oil, cinnamon oil, clove oil, peppermint oil, and walnut oil.
[0103] In some embodiments, one or more carrier oils may be animal-based. Examples of animal- based carrier oils include without limitation poultry oil, emu oil, oleo-oil, tallow oil, fish oil, fish liver oil, and cod liver oil.
[0104] In some embodiments, one or more carrier oils may comprise one or more long chain fatty acids. Long chain fatty acids may have a straight or branched chain preferably comprising 13 or more carbon atoms. Long chain fatty acids are absorbed by the lymphatic system. Formulations comprising one or more long chain fatty acids may therefore improve absorption when combined with certain mixtures of cannabinoid(s) and carrier oil(s). In some embodiments, one or more carrier oils may comprise one or more medium chain fatty acids. Medium chain fatty acids may have a straight or branched chain preferably comprising 6 - 12 carbon atoms. It is possible to use one or more lengths of fatty acids in combination.
[0105] Carrier oils employed will be safe for human consumption at the dosages provided.
[0106] As described above, certain embodiments employ Camelina oil as a carrier oil. Camelina oil is widely available from commercial sources including www.threefarmers.ca.
[0107] Other embodiments employ MCT Oil as a carrier oil. MCT Oil has naturally occurring fatty acids caprylic acid (C8:0) and capric acid (Cl0:0). MCT Oil may be derived from
coconut/palm kernel oil. MCT Oil is widely available from commercial sources including Now Foods (see https://www.nowfoods.com/sports-nutrition/mct-oil-liquid)
[0108] Marine oils are preferred carrier oils in certain embodiments. Marine oils comprise oils extracted from ocean organisms including vertebrates (e.g. fish) and non-vertebrates (e.g.
invertebrates, bacteria and sea-plants). A preferred carrier oil for use in the invention is oil extracted from krill. Neptune Krill Oil (NKO) has unique fatty acid profile, which includes EPA and DHA, plus phospholipids. In addition, NKO naturally has astaxanthin, a free radical scavenger and immune-supporting carotenoid. Krill oil, in particular NKO, is widely available from commercial sources including https://www.nowfoods.com/supplements/.
[0109] In some embodiments, the carrier oils comprise preferred ratios of omega-3 oils to omega-6 oils (on a weight per weight basis unless otherwise indicated). The following chart lists the omega- 6 and omega-3 content of various vegetable oils and foods:
[0110] About 75% of the fats in chia seeds consist of the omega-3 alpha-linolenic acid (ALA), while about 20% consist of omega-6 fatty acids (Ratio = 3.75). The ratio for Camelina oil is 2.2 (=39/18). In some embodiments, carrier oils comprise a preferred omega-3 to omega-6 ratio (on a weight per weight basis) of about 1.0 or higher, 1.5 or higher, 2.0 or higher, or 2.2 or higher.
Methods of Generating Lipid Carriers of the Invention
[0111] Several methods may be employed to generate an oral formulation of the invention.
In some embodiments, the invention provides a method for producing an emulsion of lipid carrier(s) and cannabinoid. An emulsion may be generated simply by mixing a food grade surfactant with the lipid carrier and the cannabinoid formulation. Surfactants such as Labrasol™ are satisfactory. Gentle agitation is sufficient to generate a surfactant mixture of the invention which is an emulsion, or a surfactant mixture that becomes an emulsion upon exposure to the
aqueous environment of the gastric tract. The method of generating oil-in-water emulsions generally includes the steps of (i) dissolving one or more cannabinoids and one or more lipid carriers in a polar solvent (e.g. ethanol) to obtain a cannabinoid-lipid carrier-polar solvent solution;
(ii) injecting the cannabinoid-lipid carrier-polar solvent solution into distilled water and blending to obtain a cannabinoid-lipid carrier-polar solvent emulsion; and (iii) removing the polar solvent to obtain a concentrated emulsion of lipid carrier/cannabinoid. In some embodiments, the average diameter of the droplets in the emulsion is in the range of about 100 nm to 1000 nm.
[0112] In some embodiments, the invention provides a method for producing a nanoemulsion of lipid carrier(s) and cannabinoid. The method generally including the steps of (i) dissolving one or more cannabinoids and one or more lipid carrier(s) in a polar solvent (e.g. ethanol) to obtain a cannabinoid-lipid carrier-polar solvent solution; (ii) injecting the cannabinoid-lipid carrier-polar solvent solution into distilled water and blending to obtain a cannabinoid-lipid carrier-polar solvent emulsion; and (iii) removing the polar solvent to obtain a concentrated emulsion of lipid carrier/cannabinoid. In some embodiments, the average diameter of the droplets in the
nanoemulsion is in the range of about 20 nm to 600 nm. In a preferred embodiment, the average diameter of the droplets in the emulsion is in the range of about 50 nm to 150 nm.
[0113] Without departing from the scope of the invention, any method may be employed to generate an emulsion or nanoemulsion. As those skilled in the art will be aware, many methods are available for generating emulsions and/or nanoemulsions, such as those found in Jaiswal, M. et al. 2015“Nanoemulsion: An Advanced Mode of Drug Delivery System” (3 Biotech, 5(2): 123-127), and Ting, Y. et al. 2013“Emulsion in Oral Delivery of Bioactive Lipophilic Phytochemicals” (from the book: Nutrition, Functional and Sensory Properties of Foods); see also Singh Y. et al. 2017 “Nanoemulsion: Concepts, development and applications in drug delivery” (J Control Release, 252:28-49), all of which publications are incorporated herein in their entireties.
[0114] In some embodiments, the invention provides a method for producing a liposomal formulation of lipid carrier(s) and cannabinoid. The method generally including the steps of (i) dissolving one or more lipid carrier(s) and one or more cannabinoids in a polar solvent (e.g.
ethanol) to obtain a lipid carrier-cannabinoid-polar solvent solution; (ii) adding a phospholipid to the cannabinoid-lipid carrier solution to obtain a phospholipid-cannabinoid-lipid carrier solution;
(iii) injecting the phospholipid-cannabinoid-lipid carrier solution into distilled water to obtain a suspension of liposomes; and (iv) removing the polar solvent from the liposomal suspension to obtain a concentrated liposomal suspension. In some embodiments, the average diameter of the liposomes in the suspension is in the range of about 50 nm to 1000 nm.
[0115] Without departing from the scope of the invention, any method may be employed to generate a liposome. As those skilled in the art will be aware, many methods are available for generating liposomes, such as those found in Alavi, M. et al. 2017“Application of Various Types of Liposomes in Drug Delivery Systems” (Adv Pharm Bull, 7(1): 3-9), incorporated herein in its entirety.
[0116] In some embodiments, the invention provides a method for producing micellar formulations of lipid carrier(s) and cannabinoid. The method generally including the steps of (i) dissolving one or more lipid carrier(s) and one or more cannabinoids in a water miscible solvent to obtain a solution containing a mixture of lipid carrier(s) and cannabinoid; (ii) injecting the mixture into distilled water to obtain an aqueous miscible solvent suspension of micelles; and (iii) removing the water miscible solvent to obtain a concentrated micellar formulation. In some embodiments, the average diameter of the micelles in the suspension is in the range of about 50 nm to 1000 nm.
[0117] Without departing from the scope of the invention, any method may be employed to generate a micelle. As those skilled in the art will be aware, many methods are available for generating micelles, such as those found in Xu, W. et al. 2013“Polymeric Micelles, a Promising Drug Delivery System to Enhance Bioavailability of Poorly Water-Soluble Drugs” (J Drug Deliv, 340315), incorporated herein in its entirety.
[0118] In some embodiments, the methods of the present invention may include one or more additional steps. An additional step may include (a) adding a stabilizer, carrier, buffer, excipient, or the like, to a formulation of the present invention; (b) encapsulating a formulation of the present invention. Encapsulation of cannabinoid-lipid carrier formulations can take place by trapping or dispersing cannabinoid-lipid carrier formulations within an encapsulating matrix. In some embodiments, encapsulation involves trapping cannabinoid-lipid carrier formulations within a network of crosslinked polymers. In some embodiments, encapsulation involves trapping cannabinoid-lipid carrier formulations within a network of non-crosslinked polymers. In some embodiments, encapsulation involves dispersing cannabinoid-lipid carrier formulations within the crystalline structure of a macromolecule. Examples of crystalline structure-forming
macromolecules include without limitation sugars, starches, and proteins.
Pharmaco-Analytical Testing of Cannabinoid(s) for use in Preparation of the Defined Dose Oral Formulations
[0119] Any chemical analytical method may be employed to determine the amount of the cannabinoids in the preparation used for formulating the LIDF. Many methods are available to those skilled in the art, such as those found in Thomas, BF and El Sohly, M 2015“The Analytical
Chemistry of Cannabis: Quality Assessment, Assurance, and Regulation of Medicinal Marijuana and Cannabinoid Preparations” (Elsevier). See also Wang et al. (2016) Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry. Cannabis Cannabinoid Res.; 1(1): 262- 271; and Wang et al. (2017) Quantitative Determination of Cannabinoids in Cannabis and Cannabis Products Using Ultra-High-Performance Supercritical Fluid Chromatography and Diode
Array/Mass Spectrometric Detection. J Forensic Sci.;62(3):602-6l 1.), all of which are incorporated herein in their entireties.
[0120] Testing may be performed to identify the cannabinoid content of the ground dried plant form, any other solid form or a liquid extract preparation.
[0121] Testing may be required at one step or at multiple steps in the production process. It may be first performed as a batch assay to ascertain amounts of relevant cannabinoids from a particular harvest or extraction process. The representative sample and measurement technique must be sufficient to represent all samples of the process batch within the degree of variability tolerated by the overall process, namely +/- 25% of the defined dose of each cannabinoid. Depending on the result, the cannabinoid preparation may need to be adjusted (either diluted or concentrated) to generate a cannabinoid preparation to meet the tolerance range of volume/dose range for manufacturing specifications of the UDF. The operator will have available a variety of cannabinoid diluents or concentrating processes and/or oils of known cannabinoid concentrations to adjust the preparation. Often only one cannabinoid will need to be added, the others being already at satisfactory levels. The operator can determine by simple algorithm the amount of which additives and/or which concentration steps are required to obtain the desired preparation. The final preparation of cannabinoid may again be chemically analyzed. Any final preparation which is not within tolerance levels is discarded or re-processed until desired cannabinoid levels are obtained. The final tolerance level is within +/- 25%, preferably within +/- 20%, +/- 15%, +/- 10%, +/- 5%, +/- 2% and most preferably within +/- about 1% of the desired in-going amount of each defined dose cannabinoid in the preparation used for formulating the UDF.
[0122] Alternatively stated, the UDF is expected to contain a dose of from 80% to 120% of the amount stated on product label. Preferably the range will be significantly more precise.
Analytical Identification of Terpenes and Other Cannabis Plant Components in the Cannabinoid Preparation
[0123] Depending on the extraction process employed, a variety of other plant constituents may be extracted from cannabis along with the cannabinoids. It may be desirable to identify and confirm
concentrations of these components. Terpenes, chlorophylls, other alkaloids and macromolecules may also be detected by gas chromatography, mass spectroscopy, high-pressure liquid
chromatography, or techniques standard in the art.
[0124] In certain embodiments, the signifier used with the unit dosage form product may also indicate the defined dose of such additional plant components.
Coatings and Excipients
[0125] Oral formulations of the invention may optionally further comprise additional components such as but not limited to carrier oils, stabilizers, anti -oxidants, preservatives and excipients, as further described below.
[0126] Excipients may be used for the purpose of stabilizing cannabinoids of the oral dosage forms, or to confer a therapeutic enhancement such as facilitating drug absorption, reducing viscosity, or enhancing solubility. Useful excipients include without limitation diluents, dissolving agents, solubilising agents, adjuvants, anti-adherents, binders, coatings, colorants, surfactants,
bioadhesives, polysaccharides, polymers, copolymers, bioavailability enhancing agents,
mucoadhesives, protective agents, buffers, antioxidants, dispersing agents, lubricants, sorbents, preservatives, flavor imparting agents, and any combination thereof. Excipients may include one or more pharmaceutically acceptable carriers, diluents, fillers, hinders, lubricants, glidants,
disintegrants, bulking agents, flavourants or any combination thereof. Non-limiting examples of suitable pharmaceutically acceptable carriers, diluents or fillers for use in the invention include lactose (for example, spray-dried lactose, alpha-lactose, beta-lactose), or other commercially available forms of lactose, lactitol, saccharose, sorbitol, mannitol, dextrates, dextrins, dextrose, maltodextrin, croscarmellose sodium, microcrystalline cellulose (for example, microcrystalline cellulose available under the trade mark Avicel), hydroxypropyl cellulose, L- hydroxypropyl cellulose (low substituted), hydroxypropyl methylcellulose (HPMC),
methylcellulose polymers (such as, for example, Methocel A, Methocel A4C, Methocel A15C, Methocel A4M), hydroxyethylcellulose, sodium carboxymethylcellulose, carboxym ethylene, carboxymethyl hydroxyethylcellulose and other cellulose derivatives, pre-gel atinized starch, starches or modified starches (including potato starch, com starch, maize starch and rice starch) and the like. Typically glidants and lubricants may also be included in the invention. Non-limiting examples include stearic acid and pharmaceutically acceptable salts or esters thereof (for example, magnesium stearate, calcium stearate, sodium stearyl fumarate or other metallic stearate), talc, waxes (for example, microcrystalline waxes) and glycerides, light mineral oil, PEG, silica acid or a derivative or salt thereof (for example, silicates, silicon dioxide, colloidal silicon dioxide and
polymers thereof, crospovidone, magnesium aluminosilicate and/or magnesium alumina metasilicate), sucrose ester of fatty acids, hydrogenated vegetable oils (for example, hydrogenated castor oil), or mixtures thereof or any other suitable lubricant. Suitably one or more binders may also be present in the invention and non-limiting examples of suitable binders are, for example, polyvinyl pyrrolidone (also known as povidone), polyethylene glycol(s), acacia, alginic acid, agar, calcium carragenan, cellulose derivatives such as ethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethylcellulose, dextrin, gelatin, gum arabic, guar gum, tragacanth, sodium alginate, or mixtures thereof or any other suitable
binder. Suitable disintegrants may also be present in the invention. Examples include, but are not limited to, hydroxylpropyl cellulose (HPC), low density HPC, carboxymethylcellulose (CMC), sodium CMC, calcium CMC, croscarmellose sodium; starches exemplified under examples of fillers and also carboxymethyl starch, hydroxylpropyl starch, modified starch; crystalline cellulose, sodium starch glycolate; alginic acid or a salt thereof, such as sodium alginate or their equivalents and any combination thereof.
[0127] The term“antioxidant” as used herein includes any compound or combination of compounds that prevent or slow down oxidation of components caused by the damaging reactive oxygen species (ROS). Any of the known antioxidants may be used, including but not limited to tocopherols, phospholipids (PL), phytosterols, phycocyanin, vitamins E, A and C, betacarotene, coenzyme Q10, fatty acids omega-3, omega-6 and w-9, phytoantioxidants such as polyphenols, terpenes as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, lecithin, sesamin, sesamol, sesamolin, a-tocopherol, g-tocopherol, salicylic acid, ascorbic acid, ascorbyl palmitate, fumaric acid, malic acid, sodium ascorbate and sodium meta-bisulphite, as well as chelating agents such as disodium EDTA. Pharmaceutically acceptable nutraceutical dietary supplements may also be employed as anti -oxidants including plants, alga, and lichen and may include one or more extracts of honeybee propolis, red clover, soybean, caper, almond, milk thistle, green tea, pomegranate, orange red, grape seed, bilberry, foti root, ginseng, english ivy, red algae, brown algae, green algae and lichens.
[0128] The total moisture (water) content of the ETDF may be selected to ensure appropriate stability and shelf-life for the product. Those skilled in the art may identify acceptable ranges depending on the form of ETDF selected. Softgels are particularly sensitive to water content as water will weaken and dissolve softgel gelatin capsules. Water content is typically kept below 30% and preferably below 5% of the total mass.
[0129] In preferred embodiments, certain potential contaminants are eliminated, avoided, or present at trace levels considered acceptable for human consumption. In particular, the preferred
embodiments eliminate, avoid or reduce the presence of organic solvents, pest control products, di- acetyl and ammonia.
[0130] In some embodiments, at least one emulsifying agent is used to improve the stability of the cannabinoid active ingredients in oral formulations of the present invention. The stability of an emulsion refers to the ability of the emulsion to resist change in its properties over time. An emulsifying agent may be used to modify a hydrophobic cannabinoid oil so as to enhance hydrophilicity such that the hydrophobic cannabinoid oil is more bio-available. Examples of emulsifying agents that are safe for human consumption include without limitation, Labrasol™, xanthan gum, guar gum, alginate, cyclodextrin, lecithin, cellulose, hyaluronic acid, carrageen, monoglycerides, natural emulsifiers, organic emulsifiers.
[0131] In some embodiments, oral formulations of the present invention may be formulated with modified- or sustained-release coatings or layers. Modified- or sustained-release coatings are designed to delay release of active cannabinoids for a certain period of time, to target release to a certain area of the body, or to maintain a constant drug concentration for a specific period of time with minimal side effects. Controlled release can be achieved by coating UDFs using various pharmacological technologies. For example, poly(meth)acrylate coatings have been widely used in the pharmacological industry to achieve targeted and controlled drug release. Other suitable enteric coatings include without limitation hydroxypropyl methylcellulose, poly(meth)acrylates, methyl acrylate-methacrylic acid copolymers, cellulose acetate, cellulose acetate phthalate, polyvinyl acetate phthalate, plastics plant fibres, and other types of coatings.
[0132] In some embodiments, enteric coatings may be used to delay release of cannabinoids until they reach the intestine. An enteric coating that dissolves at a pH of about 6.0 to 7.0 may be used for this purpose. An example of a suitable enteric coating that dissolves in the small intestine but not in the stomach is cellulose acetate phthalate.
[0133] In some embodiments, a long-chain fatty acid of specific length shown to be best with the specific cannabinoid or cannabinoids of interest, combined with a specific micellar particle size may be used.
[0134] In some embodiments a long-chain fatty acid of specific length shown to be best with the specific cannabinoid or cannabinoids of interest, combined with a specific micellar particle size combined with enteric coatings designed to place the release of the dosage form to a specific part of the GI tract may be used.
[0135] In a preferred embodiment, the UDF meets the requirements of a dissolution or
disintegration test that is applicable to its formulation and that is set out in European
Pharmacopoeia, The Canadian Formulary, The ETnited States Pharmacopoeia, and/or The
Pharmaceutical Codex: Principles and Practices of Pharmaceuticals, incorporated herein in its entirety.
Bioavailabilitv
[0136] A significant drawback to the use of cannabinoid-based products is the lack of a consistent and robust method of delivery. The route of administration and formulation can significantly affect the rate of cannabinoid absorption. For example, studies show that the bioavailability of THC from inhaled cannabis smoke can fluctuate between 2-56% compared to 4-20% for orally consumed cannabis (Huestis 2007; PMC ID: PMC2689518 and McGilveray 2005; PMID: 16237477, both incorporated by reference in their entireties).
[0137] Smoking can provide a rapid and efficient method of drug delivery from the lungs to the brain but these advantages are offset by the harmful effects of cannabinoid smoke, which are not appealing to many users for health or lifestyle reasons. Oral delivery is therefore a common alternative route of administration for cannabinoid products, particularly because cannabinoids can be easily incorporated into food and beverage products or ingested in tablet, pill, capsule, or similar forms.
[0138] Absorption of cannabinoids can be slower when ingested, with lower and sometimes delayed peak cannabinoid concentrations (Ohlsson 1981; PMID: 6261133), incorporated herein in its entirety. Dose, vehicle, and physiological factors such as rates of metabolism and excretion can influence cannabinoid concentrations in circulation. Variable absorption, degradation of cannabinoids in the stomach, and first-pass metabolism to active and inactive metabolites in the liver are the main reasons for the low oral bioavailability of cannabinoids. Effective oral formulations of cannabinoids are therefore essential to maximize their therapeutic effects.
[0139] An advantage of the invention is the improved bioavailability of the claimed oral formulations. Historical long chain triglycerides such as sesame oil and other vegetable oils have been added to formulations to help dissolve the lipid soluble cannabinoids The potential effect of sesame oil (mostly comprised of long-chain triglycerides (LCT)) on improving bioavailability of oral cannabinoid doses, examining only THC and CBD, was reported in Zgair et al. (2016) Am J Transl Res 20l6;8(8):3448-3459. Specifically, the AUC and Cmax of lipid-based formulations were enhanced over lipid-free formulations (c.f. Zgair Figure l/Table 3 (for THC)).
[0140] The relative bioavailability of cannabinoid formulations provided herein was determined by assessing their pharmacokinetic profiles using well known techniques such as area under the curve (AUC; which is a measure of the overall exposure of a subject to the cannabinoid, or of a liver metabolite thereof, in the plasma after a dose), Cmax (i.e. the highest concentration of cannabinoid, or a liver metabolite thereof, in the plasma that is measured after a dose) and Tmax (ie. the time
after administration of a drug when the maximum plasma cannabinoid concentration is reached) - all of these measurements are extensively described in the art.
[0141] The oral formulations of the present invention provide enhanced AUC and Cmax of the cannabinoids delivered in comparison both to lipid free formulations and/or to the LCT
formulations reported by Zgair, supra. They also provide formulations not previously investigated of other cannabinoids of interest and other lipid carriers of the identified carbon chain lengths and modifications. Formulations provided herein may optionally employ the formulation techniques, including micellar formulations, disclosed herein, and optionally with coatings specifically designed to place the capsules/tablets in a specific section of the GI tract before dissolution.
[0142] In a preferred embodiment, the invention comprises a cannabinoid oil extract with a carrier oil selected from MCT oil, camelina oil and a marine oil, forming particles of 20-600 nm diameter (95% distribution) and encapsulated in a gel capsule (hardgel or softgel). In an alternative embodiment, such capsule is coated with delayed release coating. In further preferred
embodiments the delayed release coating is triggered to resist release in the acid conditions of the stomach and to provide enhanced release elsewhere in the gut such as the small intestine (pH 6), the terminal ileum (pH 7.4) or the caecum (pH 5.7).
[0143] Figure 1 graphs the bioavailability of THC absorbed from the LCT formulation (12 mg/kg THC in sesame oil) reported by Zgair supra. Sesame oil is an LCT oil. It has high levels of Omega- 6 (co6) and low levels of Omega-3 (co3), corresponding to a: co3:co6 ratio of approximately 1 :50 (0.02).
General UDF Production Methods
[0144] Having selected the amounts and concentrations of all ingredients of the oral formulation of the invention, the ingredients will be formulated together for preparing the unit dosage form. Those skilled in the art are familiar with identifying preferred formulation techniques for the UDF. In a preferred embodiment, the UDF is a pill, tablet, capsule, film, or wafer, any of which may optionally be orally disintegrating, or a lollipop, lozenge, oil, tincture, or syrup. The formulation process will be adjusted accordingly. Pills and tablets are prepared from solid formulations.
Syrups, oils and tincture are liquid formulations. An orally disintegrating film, wafer, tablet or a lollipop or lozenge provides the UDF in an oral form wherein the active ingredients are at least partly absorbed directly in the buccal cavity. Capsules may be either solid formulations (e.g.
powders or particles in a hard-gel) or liquid formulations (e.g. oil-based formulations used in soft- gels). Oil based formulations with little or no water are typically easily encapsulated. Oil-in-water
formulations may comprise microemulsions, liposomes, nanoemulsions, micelles, and other forms known in the art.
[0145] Preferred capsule types are soft gelatin capsules (softgels) and hard gelatin capsules. Soft Gelatin Capsules (softgels) are well known in the art. Typically soft-gels are used for formulations not based on water, such as oil-based solutions, because water based solutions would dissolve the gelatin. The basic steps of softgel manufacturing are: Gelatin Preparation (the process of blending and heating granulated gelatin into a thick syrup for use in encapsulation); Fill Material Preparation (the process of preparing the non-aqueous oil or paste containing the lipid carrier and cannabinoid components that will be encapsulated); Encapsulation (the process of converting the gel mass into a thin layer of gelatin and wrapping it around the fill material to form a softgel); Drying (the process which removes excess moisture from the gelatin shell to shrink and firm up the softgel); the softgel could incorporate a Coating step (the process of coating the capsule with a coating designed to release the capsule within the digestive system); and finally Cleaning, Inspection and Sorting. Automated or semi-automated manufacturing of softgels and can be achieved using commercially available equipment, such as that provided by CapPlus Technologies, SaintyCo, and many others. Hard gelatin capsules are made of two parts, the body and a cap. This form of capsule holds dry ingredients in the form of powders, granules or tiny pellets. They may also include cannabis oils of various viscosity, such as diluted cannabis oil and concentrated cannabis extracts. The body is first filled with the mix of active ingredients and any excipients used, and then closed with the cap using either a manual or automated or semi-automated capsule filling machine, such as those
commercially available from Bosch, Zanazzi, etc. Banding of hard gelatin capsules is sometimes useful to prevent leakage.
[0146] The inventors recognize that advantages may be achieved by use of a dose form that is substantially opaque to one or both of ultraviolet and visible light, such as a photo- and/or UV- opaque gelatin capsule. A general form of this technology is described in co-owned patent application USSN 62/837848 filed 24-April-20l9, incorporated herein by reference in its entirety.
[0147] Delayed release to the gastrointestinal tract can be achieved for softgels or hard gels by enteric coatings which delay disintegration until after passing from stomach to the intestine; or by formulation techniques such as pellets which resist release until they pass into a specific intestinal domain. Such techniques are widely known in the art. An example is WIPO patent publication WO2017075215A1 to McGuffy and Bell, incorporated herein by reference in its entirety, for extended release film-coated softgel or hard-shell capsules.
[0148] A wide variety of technologies are available for a buccal or sublingual formulation such as an orally disintegrating thin film, wafer or tablet, or a lollipop, and/or lozenge. Sublingual tablets,
wafers, films and strips can be designed to rapidly disintegrate (5-15 seconds) providing rapid access to buccal cavity capillaries and avoid the hostile environment of the gastrointestinal track. Lollipops and lozenges provide a combination of buccal and gastric administration. The technologies are widely used with therapeutic agents where rapid onset is desired. (See Lamey and Lewis“Buccal and Sublingual Delivery of Drugs” Ch 2 in“Routes of Drug Administration” Ed. Florence and Salole (Butterworth- Heinemann). Orally disintegrating tablets (ODTs) of the invention can be based on solid lipid micro-pellets (SLMPs). SLMPs can be prepared using the hot melt extrusion technique and utilizing lipid carriers such as Compritol, Precirol and white beeswax either alone or in mixtures. Such ODTs demonstrate sustained drug release and a taste masking effect.
Association with Signifier
[0149] In preferred embodiments, methods and compositions of the invention may associate the disclosed formulations with one or more signifiers permitting the consumer to determine the defined dose of selected cannabinoids therein. A“signifier” means a visual mark or symbol that the consumer recognizes as referring to a specific defined dose. The signifier chosen may have elements of meaning, such as a number and unit, (e.g.“5 mg” or“10 mg” or simply“5” or“10”) or it may be an abstract signifier, where its meaning, in terms of defined dose, can be determined by reference to a standard. The meaning may be determined directly by the consumer or indirectly via a device.
[0150] The signifier may be associated directly with the formulation by such means as embossing, or by colour, pattern or shape feature. Alternatively, the signifier may be associated with the packaging. The packaging may include signifiers directly interpreted by consumers or signifiers which are machine readable codes. In all embodiments, the signifier allows the consumer to determine the defined dose of selected cannabinoids therein.
[0151] The signifier may be associated directly with the UDF before, during or after encapsulation by such means as edible ink(s) imprinted on the surface of the capsule, or by embossing, by engraving (such as laser-engraving), or by color, pattern or shape feature. The edible ink applied to the capsule may include shellac from about 10% to about 30% by weight, about 20% to 70% by weight of at least one solvent, and at least one soluble or insoluble pigment from about 10% wt to about 40% wt. The shellac provides structure, enhances adherence to the printing plate and capsule, and/or act as a pigment carrier. An edible ink formulation may include 10% wt to about 30% wt shellac.
Packaging
[0152] After a UDF is manufactured, storage and delivery to consumer may be provided by:
a. Packaging the UDF individually in a blister pack; or
b. Packaging multiple UDFs in a re-sealable package.
[0153] The UDF is preferably provided in a sealed package, which functions as a barrier limiting moisture fluctuation, reducing oxidation, and enhancing shelf-life, etc. The packaging is optionally a gas-impermeable container having a hermetic closure which in the context of the present invention includes a blister pack. The UDFs may be individually sealed and packaged in blister packs. The blister packs may be designed to be child resistant and/or senior friendly in order to increase safety and convenience. While physically protecting the UDFs, the blister pack controls humidity and is impermeable to gas exchange thereby enhancing shelf life.
[0154] Examples of the substantially gas exchange impermeable packaging include, but are not limited to, Al/Al blister, and Al-polychloro-3-fluoroethylene homopolymer/P VC laminate blister. Alternatively, the sealed package may be a re-sealable multi- package impermeable to gas exchange.
[0155] UDFs of the invention may be expelled from production into the open blister cavities. Cavity depth and shape must be suitable for the unit. The open blister cavity is then sealed with a gas impermeable membrane to maintain quality of product and to reduce dehydration, rehydration or oxidation. To eliminate oxidation altogether, the packaging may be performed in an inert gas atmosphere. Optionally the blister is packed in an inert gas atmosphere such as nitrogen gas comprising little or no oxygen. To achieve this objective, the final sealing step of the packaging method may be operated in the inert gas atmosphere in a gas enclosure protected from ambient air.
EXAMPLES
Example 1 : Use of lipid carriers to enhance cannabinoid bioavailabilitv.
[0156] Oral formulations of the invention are tested to determine key pharmacokinetic (PK) parameters and to identify which lipid carriers provide enhanced exposure over time
(bioavailability). PK assays are used to identify plasma concentration over time, area under the curve (AUC) exposure over 24hrs, systemic clearance rate (CL) and systemic bioavailability. The combination is also tested against the individual components. The 24hr exposure identifies if the UDF should be administered QD (once a day) or BID (x 2 a day) or more often, or less often.
[0157] Standard PK models are widely available and can be performed with a commercial service. A preferred method is to use at least 4 Male Sprague Dawley rats (210-230 g) who receive either an intravenous (i.v. 2, 5, 10 mg/kg) or oral (5, 10, 12, 20 and/or 30 mg/kg) dose of each compound
separately, or combined in formulation. Blood, urine, cerebrospinal fluid (CSF) or other appropriate biological fluid is removed at periodic intervals. The biological fluid is tested for active compound(s) in order to construct concentration vs. time profiles. These data are analyzed and pharmacokinetic parameters are calculated in order to assess in vivo pharmacokinetic activity.
[0158] The study uses a fixed dose of each component in the combination in a fixed vehicle formulation. In one embodiment PEG (polyethylene-glycol) is an excipient, or alternatively a long chain fatty acid oil carrier. Typically, components are prepared from a powder form, first in 5% ETOH, then with 40% PEG. The components are combined and topped up with distilled water to 100% volume. If components are not sufficiently soluble, PEG may be increased to 60% and also add 10% PG. By way of example, a PK study may be conducted at 10 mg/kg dose for an oral formulation. 2 mg/kg may be used for IV injection as a comparison. In either case, plasma samples are collected over a 24 hr time-period to determine bioavailability. Plasma samples are tested by HPLC or LC-MS/MS to obtain PK parameters. 4 rats per each route (total n=6) is typically sufficient.
[0159] Plasma and other tissue samples are tested for the administered cannabinoids and the lipid carrier administered to the animal. The samples are also tested for significant metabolites, some of which may have more potent effects than the parent administered compounds. The samples may also be used to determine baseline levels of serum biomarkers which are relevant to the
development or treatment of the complex disease models set out further below. Many serum biomarkers are of great interest in the development or treatment of complex disorders. Biomarkers of interest to the compositions of the invention include IL-6, NFkB, TNF alpha, C-reactive protein, and any other biomarker known to be or potentially implicated in the development of a disease or disorder.
Example 2: Comparison of Carrier Oils
[0160] The experiment of Example 1 was performed with the following modifications: THC was prepared by Emerald Health Therapeutics (Victoria, BC) in ethanol-extracted cannabis concentrates diluted in each of a selection of carrier oils including: sesame oil (Sigma-Aldrich, SKU #S3547), krill oil (Grizzly Pet Products, SKU #B00VEZHL7K), camelina oil (Neptune Wellness Solutions, Product Code: RCAMO001) and camelina oil with Labrasol™ surfactant (Gattefosse, Product Code: 160865). The latter camelina oil and Labrasol™ surfactant formulation was prepared by slowly adding Labrasol™ to camelina oil heated to 60-70°C. The mixture was gently agitated and THC extract slowly added, followed by further gentle agitation to ensure THC is fully solubilized.
For the oral-administered groups THC was formulated to a dose of l2mg/kg in the carrier oil. The volume of administration is adjusted per individual animal’s body weight.
[0161] Rats are orally administered one of the above formulations by oral gavage (volume up to 0.5ml) at time zero. 0.25ml blood was collected from the arterial catheter at 60, 180, 300, 480, 720 and 1440 minutes after drug treatment. Blood samples were promptly centrifuged to separate plasma, stored in duplicate and kept at -80°C until ready for analysis.
[0162] Blood samples were purified and analyzed with LCMS for measurement of cannabinoid levels. Each sample was measured for levels of THC, 1 l-OH-THC, and THC-COOH (also known as 1 l-Nor-9-carboxyTHC, this compound is a non-psychoactive liver metabolite of THC with a long half-life). Pharmacokinetic parameters, including Cmax and AUC, were calculated by PK Solver, as described in Zhang et al. Comput. Methods Programs Biomed., 2010;99(3):306-314
[0163] Figure 2 sets out observed results of the experiment. The THC and emulsified camelina oil combination showed increased THC bioavailability (Cmax =l47 ng/ml; AUCo-t=l028.2 ng/ml*hr-) at all timepoints versus the other formulations (Figure 2). The non-emulsified camelina oil formulation also showed increased THC bioavailability (Cmax=l37.6 ng/ml; AUC0-t=65l.O ng/ml*hr) over the krill oil (Cmax=l0l.7 ng/ml; AUCo-t=588.8 ng/ml*hr) and sesame oil (Cmax=93.7 ng/ml; AUCo-t=407.9 ng/ml*hr) formulations.
[0164] Increased THC bioavailability with both the emulsified and non-emulsified camelina formulations, and the krill formulation was further supported by observed increases in THC liver metabolites 1 l-OH-THC (Figure 3) and THC-COOH (Figure 4) as compared to the sesame oil formulation.
[0165] Taken together, the results show that camelina oil provides a significant enhancement to bioavailability of THC taken orally. This effect is particularly enhanced when the camelina is formulated with a surfactant such that it becomes an emulsion upon administration to the aqueous gut environment. Krill oil also provides an enhanced bioavailability compared to sesame oil.
Camelina oil and krill oil are examples of carrier oils having a relatively high ratio of Omega-3 to Omega-6 lipids of about 1.0 or greater. These observations lead the inventors to conclude that such formulations will provide significantly different physiological effects compared to THC products taken with Omega-3/Omega-6 ratios below 1.0.
[0166] Thus, in certain embodiments, THC is provided in camelina oil, preferably mixed with surfactant, where with THC effects on the consumer are substantially enhanced compared to THC without a carrier oil or surfactant. Alternative preferred products, include lower dose THC capsules (e.g. 4mg THC) which are provided in a carrier oil having a ratio of Omega-3 to Omega-6 lipids of
about 1.0 or greater, such as a camelina oil emulsion, which due to enhanced bioavailability, have the effect of lOmg THC capsules provided without carrier oil, or with a long chain fatty acid carrier such as sesame oil which has a low ratio of Omega-3 to Omega-6 lipids of below 1.0.
[0167] These examples are derived from the observations presented in Figures 2-4 that the AUC and Cmax of the camelina emulsion formulation is significantly greater, for the same dose, as the sesame formulation.
[0168] Summarized otherwise, the invention can be described as a method to enhance the effect of THC to a consumer by providing it in a carrier oil having a high ratio of Omega-3 to Omega-6 lipids of about 1.0 or greater, and optionally with such oil in an oil carrier emulsion, most preferably where the carrier oil is camelina oil. Another description is a“high-impact THC capsule” where a lower dose THC capsule according to the invention has the physiological effect of a higher dose prior art capsule. In some embodiments, the invention provides a physiological impact of about 2.5 times higher than a prior art dose of THC in a prior art formulation.
[0169] The results of Figure 1 are summarized in the following Table 2.
Table 2
[0170] The results of Figure 2 are summarized in the following Table 3.
[0172] Product embodiments that take advantage of these surprising properties are set out in Example 3.
Animal models of complex disease or condition
[0173] Compositions of the invention are tested in models corresponding to the disease and/or conditions proposed for use. These may be selected from among models of anxiety, pain, sleep induction, calmness induction, alertness induction, weight control, weight loss, obesity, diabetes and metabolic syndrome.
[0174] For any of the animal assays herein (including human testing), successful treatment may be identified according to the behavioural results identified in the assay, or by measuring biomarkers of disease progression/treatment, such as IL-6, NFkB, TNF alpha, C-reactive protein, and any other biomarker known to be or potentially implicated in the development of the disease or disorder being studied. Those skilled in the art are familiar with the wide variety of models available for further testing the products of the invention.
Example 3: Unit Dosage Form (TJDF) Oral Capsule Embodiments
Example 3-1 - Island Mist Capsule (HardGel; Low-Dose; 250mg volume)
Example 3-3 - TimeWarp A3 CAPSULE (Softgel; Low-Dose THC; 250mg volume)
Example 3-4 - Island Mist Capsule (HardGel; Low-Dose THC; Medium Dose CBD; 250mg volume)
[0175] Certain preferred embodiments of the invention are set out in Table 5
Table 5: Preferred embodiments of the invention
[0176] The compositions and methods described herein are illustrative and not intended to be limiting on the claims of the invention more particularly set out below.
Claims
1. A cannabinoid formulation for oral administration, comprising:
one or more cannabinoids selected from the group consisting of:
0.1 - 100 mg tetrahydrocannabinol (THC);
0.1 - 750 mg tetrahydrocannabinolic acid (THCA);
0.1 - 750 mg cannabidiol (CBD);
0.1 - 750 mg cannabidiolic acid (CBDA); and
0.1 - 750 mg cannabigerol (CBG);
0.1 - 750 mg cannabinchromene (CBC);
and
a lipid carrier comprising or consisting of camelina oil.
2. A cannabinoid formulation for oral administration, comprising:
one or more cannabinoids selected from the group consisting of:
0.1 - 100 mg tetrahydrocannabinol (THC);
0.1 - 750 mg tetrahydrocannabinolic acid (THCA);
0.1 - 750 mg cannabidiol (CBD);
0.1 - 750 mg cannabidiolic acid (CBDA);
0.2 - 750 mg cannabinchromene (CBC);
0.1 - 750 mg cannabigerol (CBG); and
a lipid carrier comprising one or more lipids selected from the group consisting of: camelina oil;
a marine phospholipid;
krill oil;
fish oil;
chia seed oil;
flaxseed oil; and
an oil comprising an omega-3 to omega-6 ratio of about 1.0 or higher, 1.5 or higher, 2.0 or higher, or 2.2 or higher.
3. The cannabinoid formulation of claim 1 or 2, wherein one or more of the one or more cannabinoids is dissolved and/or suspended in the lipid carrier.
4. The cannabinoid formulation of any one of claims 1 to 3 in a unit dosage form selected from a pill, tablet, capsule, film, wafer, lollipop, lozenge, oil, tincture or syrup.
5. The cannabinoid formulation of claim 4, wherein the formulation is an orally
disintegrating tablet, film, or wafer.
6. The cannabinoid formulation of claim 4, wherein the formulation is a pill or tablet and further comprises an enteric coating for containing the one or more cannabinoids and the lipid carrier.
7. The cannabinoid formulation of any one of claims 4 to 6, wherein the formulation is a pill, tablet, or capsule and further comprises an outer shell that is substantially opaque to one or both of ultraviolet and visible light.
8. The cannabinoid formulation of any one of claims 1-7 further comprising a further carrier oil.
9. The cannabinoid formulation of any one of claims 1-8, further comprising a stabilizer.
10. The cannabinoid formulation of any one of claims 1-9, wherein the lipid carrier is
present in the form of an emulsion.
11. The cannabinoid formulation of claim 10, wherein the emulsion is a nanoemulsion.
12. The cannabinoid formulation of any one of claims 1 to 11, wherein upon administration of the formulation to a subject, a target bioavailability in the subject is achieved,
13. The cannabinoid formulation of any one of claims 1-12 wherein one or more of the cannabinoids is in the form of an organic solvent-based extract of cannabis.
14. The cannabinoid formulation of any one of claims 1-13, further comprising at least one further cannabinoid selected from the group consisting of CBGA and
tetrahydrocannabivarin (THCV).
15. The cannabinoid formulation of any one of claims 1-14, comprising CBD in an amount between 10-50 mg.
16. The cannabinoid formulation of any one of claims 1-15, comprising 25 mg CBD.
17. The cannabinoid formulation of any one of claims 1-16 comprising 500 mg CBD.
18. The cannabinoid formulation of any one of claims 3-17, wherein the cannabinoid is evenly dispersed within at least a portion of the unit dosage form.
19. The cannabinoid formulation of any one of claims 3-18, wherein a signifier which
signifies a cannabinoid dosage is associated directly with the unit dosage form by embossing, or by colour, pattern or shape feature.
20. The cannabinoid formulation of claim 19 wherein the signifier is adapted to be directly interpreted by a consumer and/or is a machine-readable code.
21. The cannabinoid formulation of any one of claims 3-20, wherein the unit dosage form is contained in an individual blister pack sealed in an inert gas atmosphere comprising little or no oxygen.
22. The cannabinoid formulation of any one of claims 3-21, wherein the lipid carrier is present in the form of a nanoemulsion comprising lipid particles having an average particle size of about 20-100, 20-200, 20-300, 20-400, 20-500, 20-600, 100-300, 200- 500, or l00-600nm.
23. The cannabinoid formulation of any one of claims 1-22, wherein the lipid carrier
comprises medium-chain fatty acids (MCFAs) comprising or consisting of 12-16 carbon atoms or long-chain fatty acids (LCFAs) comprising or consisting of 13 or more carbon atoms.
24. The cannabinoid formulation of any one of claims 1-23, wherein the formulation further comprises a surfactant, and/or is formulated to provide an emulsion upon exposure to a user’ s gut.
25. The cannabinoid formulation of claim 24, wherein the surfactant is Labrasol™.
26. The cannabinoid formulation of claim 24 or 25, wherein the formulation comprises a defined dose or combination dose of cannabinoid(s) selected from the list consisting of (each cannabinoid milligram amount about or equal to):
a. 25mg THCA and 2mg THC;
b. 25mg THC;
c. lmg THCA, 25mg CBDA, and 2mg CBD;
d. lmg THCA and 25mg CBD;
e. 25mg THCA, 2mg THC, 25mg CBDA, and 2mg CBD;
f. 25mg THCA, 2mg THC, and 2mg CBD;
g. 25mg THC and 25mg CBD;
h. 25mg THC and 2mg CBD;
i. lmg THC, 25mg CBD; 25mg CBG, and 25mg CBC
j . 25mg THC and 25mg THCV;
k. 9mg THCA and lmg THC;
l. lOmg THC;
m. 9mg THCA, lmg THC, 9mg CBDA, and lmg CBD;
n. 9mg THCA, lmg THC, and lOmg CBD;
o. lOmg THC and lmg CBD;
p. lOmg THC and lOmg THC V;
q. 600mg THC;
r. 600mg THCA and 50mg THC;
s. lOOmg THC;
t. 600mg CBDA;
u. 25mg THCA, 600mg CBDA, and 60mg CBD;
v. lOOmg CBD;
w. 4mg THC and lOOmg CBD;
x. 600mg CBD;
y. 25mg THC and 600mg CBD;
z. 600mg CBG;
aa. 300mg THCA and 300mg CBDA;
bb. 300mg THCA, 30mg THC, 300mg CBDA, and 30mg CBD; cc. 300mg THCA and 30mg CBD;
dd. 300mg THCA, 30mg THC, and 300mg CBD;
ee. lOOmg THC and lOOmg CBD;
ff. lOOmg THC and 30mg CBD;
gg. 300mg THC and 300mg CBG;
hh. 300mg THC and 300mg CBC;
ii. 300mg CBD and 300mg CBG;
jj. 300mg CBD and 300mg CBC;
kk. 300mg CBD, 300mg CBG, and 300mg CBC;
11. lOmg THC, 250mg CBD, 250mg CBG, and 250mg CBC; mm. lOOmg THC and 500mg THCV;
nn. 300mg CBD and 300mg THCV;
oo. lOOmg CBD and lOOmg THCV;
pp. lmg THC and 9mg THCA;
qq. lmg THC and 9mg THCA;
rr. lOmg THC;
ss. lOmg THC and 9 mg CBD;
tt. lOmg THC and lOmg CBD;
uu. lmg THC and 25mg CBD;
vv. lOOmg THC and 3mg CBG;
ww. lmg THC and lOmgCBD;
xx. lOmg THCV and lOmg CBD;
yy. lmg THC and 20mg CBD;
zz. lmg THC and 30mg CBD;
aaa. lmg THC and 40mg CBD;
bbb. 5mg THC;
ccc. 5mg THC and lOmg CBD;
ddd. 5mg THC and 25mg CBD;
eee. 10 mg THC, 2mg CBG and lmg CBC;
fff. 6mg THC, 3mg CBG and 3mg CBC; and
ggg. 6mg CBD, 3mg CBG, and 2mg CBC.
27. The cannabinoid formulation of any one of claims 1-26 wherein the lipid carrier
comprises or consists of camelina oil.
28. The cannabinoid formulation of claim 12, wherein the formulation comprises a first defined dose amount of a dosed cannabinoid, further wherein the administration is by oral administration, and wherein the target bioavailability is a bioavailability of THC or a THC liver metabolite which is greater than a baseline bioavailability, the baseline bioavailability being that achievable from oral administration to the subject of a control composition containing the first defined dose amount of the dosed cannabinoid in a carrier comprising at least 90%, or consisting of, sesame oil.
29. The cannabinoid formulation of claim 28, further wherein the dosed cannabinoid is THC and wherein the cannabinoid formulation comprises about 30-50% of the defined dose amount of THC in an emulsion.
30. The cannabinoid formulation of claim 28 or 29, wherein the target bioavailability is a THC or THC liver metabolite bioavailability in the subject that is at least 140%, as measured by subject Cmax and/or subject AUC, of the baseline bioavailability.
31. The cannabinoid formulation of claim 30, wherein the target bioavailability is a THC or THC liver metabolite bioavailability in the subject that is: (i) at least 108.5%, at least 146.9%, at least 159.6%, or at least 200%, as measured by subject Cmax, and/or (ii) at least 144.3%; at least 159.6%, at least 200%, or at least 252.1%, as measured by subject AUC, of the baseline bioavailability.
32. The cannabinoid formulation of any one of claims 28-31, wherein the target
bioavailability is a bioavailability of: THC; l l-OH-THC; and/or THC-COOH.
33. The cannabinoid formulation of any one of claims 6-32, comprising an enteric coating for containing the one or more cannabinoids and the lipid carrier, wherein the enteric
coating degrades, dissolves, or otherwise provides a release of the cannabinoid and the lipid carrier in an environment having a pH value of below about 5.5, at about 5.5 or greater, at about 6.0 to about 6.5, at about 6.5 to 7.5, or greater than about 7.5.
34. The cannabinoid formulation of any one of claims 1 to 33, wherein the one or more cannabinoids in present in a defined dose.
35. A method of administering one or more cannabinoids to a subject, comprising orally administering to the subject a formulation comprising one or more cannabinoids selected from the group consisting of:
0.1 - 100 mg tetrahydrocannabinol (THC);
0.1 - 750 mg tetrahydrocannabinolic acid (THCA);
0.1 - 750 mg cannabidiol (CBD);
0.1 - 750 mg cannabidiolic acid (CBDA);
0.1 - 750 mg cannabinchromene (CBC); and
0.1 - 750 mg cannabigerol (CBG); and
a lipid carrier comprising one or more lipids selected from the group consisting of: camelina oil;
a marine phospholipid;
fish oil;
krill oil;
chia seed oil;
flaxseed oil; and
an oil comprising an omega-3 to omega-6 ratio of about 1.0 or higher, 1.5 or higher, 2.0 or higher, or 2.2 or higher.
36. A method of administering one or more cannabinoids to a subject, comprising orally administering to the subject a formulation comprising one or more cannabinoids selected from the group consisting of:
0.1 - 100 mg tetrahydrocannabinol (THC);
0.1 - 750 mg tetrahydrocannabinolic acid (THCA);
0.1 - 750 mg cannabidiol (CBD);
0.1 - 750 mg cannabidiolic acid (CBDA);
0.1 - 750 mg cannabinchromene (CBC); and
0.1 - 750 mg cannabigerol (CBG); and
a lipid carrier comprising or consisting of camelina oil.
37. A method of administering a therapeutically and/or psychotropically effective amount of one or more cannabinoids to a subject, comprising orally administering to the subject a cannabinoid formulation of any one of claims 1-33.
38. The method of any of claims 35 to 37 wherein the subject is in need of treatment for pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes, metabolic syndrome, nausea (acute or anticipatory), epilepsy, spasticity, schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, bacterial and/or fungal infection, fibromyalgia, appetite enhancement and/or appetite suppression.
39. A method of administering a therapeutically and/or psychotropically effective amount of one or more cannabinoids to a subject, the method comprising orally administering to the subject a cannabinoid formulation comprising:
one or more cannabinoids selected from the group consisting of:
0.1 - 100 mg tetrahydrocannabinol (THC);
0.1 - 750 mg tetrahydrocannabinolic acid (THCA);
0.1 - 750 mg cannabidiol (CBD);
0.1 - 750 mg cannabidiolic acid (CBDA);
0.1 - 750 mg cannabinchromene (CBC);
and
0.1 - 750 mg cannabigerol (CBG); and
a lipid carrier comprising one or more lipids selected from the group consisting of: camelina oil;
a marine phospholipid;
krill oil;
fish oil;
chia seed oil;
flaxseed oil; and
an oil comprising an omega-3 to omega-6 ratio of about 1.0 or higher, 1.5 or higher, 2.0 or higher, or 2.2 or higher.
40. A method of administering a therapeutically and/or psychotropically effective amount of one or more cannabinoids to a subject, the method comprising orally administering to the subject a cannabinoid formulation comprising:
one or more cannabinoids selected from the group consisting of:
0.1 - 100 mg tetrahydrocannabinol (THC);
0.1 - 750 mg tetrahydrocannabinolic acid (THCA);
0.1 - 750 mg cannabidiol (CBD);
0.1 - 750 mg cannabidiolic acid (CBDA);
0.1 - 750 mg cannabinchromene (CBC); and
0.1 - 750 mg cannabigerol (CBG); and
a lipid carrier comprising or consisting of camelina oil.
41. The method of claim 39 or 40 , wherein one or more of the one or more cannabinoids is dissolved and/or suspended in the lipid carrier.
42. The method of any one of claims 39 to 41, wherein the cannabis formulation is in a unit dosage form selected from a pill, tablet, capsule, film, wafer, lollipop, lozenge, oil, tincture or syrup.
43. The method of claim 42, wherein the formulation is an orally disintegrating tablet, film, or wafer.
44. The method of claim 43, wherein the formulation is a pill or tablet and further comprises an enteric coating for containing the one or more cannabinoids and the lipid carrier.
45. The method of any one of claims 42 to 44, wherein the formulation is a pill, tablet, or capsule and further comprises an outer shell that is substantially opaque to one or both of ultraviolet and visible light.
46. The method of any one of claims 39-45 wherein the formulation further comprises a further carrier oil.
47. The method of any one of claims 39-46, wherein the formulation further comprises a stabilizer.
48. The method of any one of claims 39-47, wherein the lipid carrier is present in the
formulation in the form of an emulsion.
49. The method of claim 48, wherein the emulsion is a nanoemulsion.
50. The method of any one of claims 39 to 49, wherein upon administration of the
cannabinoid formulation to a subject, a target bioavailability in the subject is achieved,
51. The method of any one of claims 39-50 wherein one or more of the cannabinoids in the formulation is in the form of an organic solvent-based extract of cannabis.
52. The method of any one of claims 39-51, further comprising at least one further
cannabinoid selected from the group consisting of CBGA, and tetrahydrocannabivarin (THCV).
53. The method of any one of claims 39-52, comprising CBD in an amount between 10-50 mg.
54. The method of any one of claims 39-53, comprising 25 mg CBD.
55. The method of any one of claims 39-54 comprising 500 mg CBD.
56. The method of any one of claims 42-55, wherein the cannabinoid is evenly dispersed within at least a portion of the unit dosage form.
57. The method of any one of claims 42-56, wherein the formulation further comprises a signifier which signifies a cannabinoid dosage is associated directly with the unit dosage form by embossing, or by colour, pattern or shape feature.
58. The method of claim 57 wherein the signifier is adapted to be directly interpreted by a consumer and/or is a machine-readable code.
59. The method of any one of claims 42-58, wherein the unit dosage form is contained in an individual blister pack sealed in an inert gas atmosphere comprising little or no oxygen.
60. The method of any one of claims 42-59, wherein the lipid carrier is present in the
formulation in the form of a nanoemulsion comprising lipid particles having an average particle size of about 20-100, 20-200, 20-300, 20-400, 20-500, 20-600, 100-300, 200- 500, or l00-600nm.
61. The method of any one of claims 39-60, wherein the lipid carrier comprises medium- chain fatty acids MCFAs comprising or consisting of 12-16 carbon atoms or long-chain fatty acids LCFAs comprising or consisting of 13 or more carbon atoms.
62. The method of any one of claims 39-61, wherein the formulation further comprises a surfactant.
63. The method of claim 62, wherein the formulation comprises the one or more
cannabinoids an emulsion.
64. The method of claim 62 or 63, wherein the formulation comprises a defined dose or combination dose of cannabinoid(s) selected from the list consisting of (each cannabinoid milligram amount about or equal to):
a. 25mg THCA and 2mg THC;
b. 25mg THC;
c. lmg THCA, 25mg CBD A, and 2mg CBD;
d. lm
e. g THCA and 25mg CBD;
f. 25mg THCA, 2mg THC, 25mg CBD A, and 2mg CBD;
g. 25mg THCA, 2mg THC, and 2mg CBD;
h. 25mg THC and 25mg CBD;
i. 25mg THC and 2mg CBD;
j . lmg THC, 25mg CBD; 25mg CBG, and 25mg CBC;
k. 25mg THC and 25mg THCV;
l. 9mg THC A and lmg THC;
m. lOmg THC;
n. 9mg THC A, lmg THC, 9mg CBD A, and lmg CBD;
o. 9mg THC A, lmg THC, and lOmg CBD;
p. lOmg THC and lmg CBD;
q. lOmg THC and lOmg THC V;
r. 600mg THC;
s. 600mg THCA and 50mg THC;
t. lOOmg THC;
u. 600mg CBD A;
v. 25mg THCA, 600mg CBD A, and 60mg CBD;
w. lOOmg CBD;
x. 4mg THC and lOOmg CBD;
y. 600mg CBD;
z. 25mg THC and 600mg CBD;
aa. 600mg CBG;
bb. 300mg THCA and 300mg CBD A;
cc. 300mg THCA, 30mg THC, 300mg CBD A, and 30mg CBD; dd. 300mg THCA and 30mg CBD;
ee. 300mg THCA, 30mg THC, and 300mg CBD;
ff. lOOmg THC and lOOmg CBD;
gg. lOOmg THC and 30mg CBD;
hh. 300mg THC and 300mg CBG;
ii. 300mg THC and 300mg CBC;
jj. 300mg CBD and 300mg CBG;
kk. 300mg CBD and 300mg CBC;
11. 300mg CBD, 300mg CBG, and 300mg CBC;
mm. lOmg THC, 250mg CBD, 250mg CBG, and 250mg CBC; nn. lOOmg THC and 500mg THCV;
oo. 300mg CBD and 300mg THCV;
pp. lOOmg CBD and lOOmg THCV;
qq. 10 mg THC, 2mg CBG and lmg CBC;
rr. 6mg THC, 3mg CBG and 3mg CBC; and
ss. 6mg CBD, 3mg CBG, and 2mg CBC
65. The method of any one of claims 39-64 wherein the lipid carrier comprises or consists of camelina oil.
66. The method of claim 65, wherein the formulation comprises a first defined dose amount of a dosed cannabinoid, further wherein the administration is by oral administration, and wherein the target bioavailability is a bioavailability of THC or a THC liver metabolite which is greater than a baseline bioavailability, the baseline bioavailability being that achievable from oral administration to the subject of a control composition containing the first defined dose amount of the dosed cannabinoid in a lipid carrier comprising at least 90% sesame oil.
67. The method of claim 66, further wherein the dosed cannabinoid is THC and wherein the cannabinoid formulation comprises about 30-50% of the defined dose amount of THC in an emulsion.
68. The method of claim 66 or 67, wherein the target bioavailability is a THC or THC liver metabolite bioavailability in the subject that is at least 140%, as measured by subject Cmax and/or subject AUC, of the baseline bioavailability.
69. The method of claim 68, wherein the target bioavailability is a THC or THC liver
metabolite bioavailability in the subject that is: (i) at least 108.5%, at least 146.9%, at least 159.6%, or at least 200%, as measured by subject Cmax, and/or (ii) at least 144.3%; at least 159.6%, at least 200%, or at least 252.1%, as measured by subject AUC, of the baseline bioavailability.
70. The method of any one of claims 66-69, wherein the target bioavailability is a
bioavailability of: THC; l l-OH-THC; and/or THC-COOH.
71. The method of any one of claims 44-70, comprising an enteric coating for containing the one or more cannabinoids and the lipid carrier, wherein the enteric coating degrades, dissolves, or otherwise provides a release of the cannabinoid and the lipid carrier in an environment having a pH value of below about 5.5, at about 5.5 or greater, at about 6.0 to about 6.5, at about 6.5 to 7.5, or greater than about 7.5.
72. The method of any one of claims 35-71, wherein the subject has a disease or disorder treatable by the administration of the one or more cannabinoids.
73. The method of claim 72, wherein the disease or disorder is selected from the group
consisting of: pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes, metabolic syndrome, nausea
(acute or anticipatory), epilepsy, spasticity, schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, bacterial and/or fungal infection, fibromyalgia, appetite enhancement, appetite suppression, and any combination thereof.
74. The method of any one of claims 43 to 73, wherein the one or more cannabinoids is present in a defined dose.
75. Use of the formulation of any one of claims 1-34 for treatment of a disease or disorder in the subject, wherein the disease or disorder is selected from the group consisting of: pain, inflammation, anxiety, depression, insomnia, sleep disorders, lack of energy, lack of alertness, weight gain, obesity, diabetes, metabolic syndrome, nausea (acute or anticipatory), epilepsy, spasticity, schizophrenia, bi-polar disorder, cancer and neoplasia, chronic pain, osteoarthritic pain, bacterial and/or fungal infection, fibromyalgia, appetite enhancement, appetite suppression, and any combination thereof.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/271,146 US20210186870A1 (en) | 2018-08-27 | 2019-08-26 | Improved cannabinoid bioavailability |
EP19854153.4A EP3843763A4 (en) | 2018-08-27 | 2019-08-26 | Improved cannabinoid bioavailability |
CA3110447A CA3110447A1 (en) | 2018-08-27 | 2019-08-26 | Improved cannabinoid bioavailability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862723229P | 2018-08-27 | 2018-08-27 | |
US62/723,229 | 2018-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020044118A1 true WO2020044118A1 (en) | 2020-03-05 |
Family
ID=69645043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2019/000964 WO2020044118A1 (en) | 2018-08-27 | 2019-08-26 | Improved cannabinoid bioavailability |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210186870A1 (en) |
EP (1) | EP3843763A4 (en) |
CA (1) | CA3110447A1 (en) |
WO (1) | WO2020044118A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021022378A1 (en) * | 2019-08-08 | 2021-02-11 | Neptune Wellness Solutions Inc. | Oral formulations of cannabis extracts and methods of making same |
WO2021041404A1 (en) * | 2019-08-26 | 2021-03-04 | Filipetto Gianna Marie | Method and apparatus for the infusion of cannabinoids into a shelf-stable food composition |
US11110372B2 (en) | 2018-08-08 | 2021-09-07 | Neptune Wellness Solutions Inc. | Cold extraction method for cannabinoids and terpenes from cannabis by organic solvents |
US11166933B2 (en) | 2018-05-03 | 2021-11-09 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
EP3987943A1 (en) * | 2020-10-21 | 2022-04-27 | Corn Products Development, Inc. | Cannabinoid emulsions |
WO2022122904A1 (en) * | 2020-12-09 | 2022-06-16 | Chanelle Mccoy Cbd Limited | A delayed-release capsule of cannabidiol |
DE202022001128U1 (en) | 2022-05-09 | 2022-08-29 | Gabriele Blume | Nanoemulsions based on the emulsifier Imwitor 375 (glyceryl citrate/lactate/linoleate/oleate) and a coemulsifier to increase the bioavailability of poorly soluble, natural bioactive substances after oral intake. |
US11478443B2 (en) | 2018-02-07 | 2022-10-25 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
IT202100014909A1 (en) | 2021-06-08 | 2022-12-08 | Velleja Res S R L | OILY FORMULATIONS OF CANNABINOIDS |
US11712456B2 (en) | 2018-04-09 | 2023-08-01 | Portland Technology Holdings Llc | Hemp extract for treatment of pain in animals |
WO2024095090A1 (en) * | 2022-11-01 | 2024-05-10 | Aker Biomarine Antarctic As | Phospholipid compositions for delivery of therapeutic compounds |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023527629A (en) * | 2020-03-20 | 2023-06-30 | ザ・クイーンズ・メディカル・センター | cannabinoid composition |
NL2028708B1 (en) * | 2021-07-13 | 2023-01-18 | Stabican B V | Process for preparing cannabinoid-containing particles |
PL440642A1 (en) * | 2022-03-15 | 2023-09-18 | Healthcann Spółka Z Ograniczoną Odpowiedzialnością | Composition forming a stable monodisperse emulsion in water containing a fat-soluble active substance |
WO2023212170A1 (en) * | 2022-04-29 | 2023-11-02 | Abstrax Tech Inc. | Endogenous stabilization of cannabinoids |
WO2024073849A1 (en) * | 2022-10-07 | 2024-04-11 | Canaquest Medical Corp. | Composition for treating epilepsy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017045053A1 (en) * | 2015-09-18 | 2017-03-23 | Prati, Donaduzzi & Cia Ltda | Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017012434A2 (en) * | 2014-12-12 | 2018-02-20 | Ojai Energetics Pbc | microencapsulated cannabinoid compositions |
US10765658B2 (en) * | 2016-06-22 | 2020-09-08 | Mastix LLC | Oral compositions delivering therapeutically effective amounts of cannabinoids |
CA3025080A1 (en) * | 2016-07-03 | 2018-01-11 | 3277991 Nova Scotia Limited D/B/A Truro Herbal Co. | Cannabis compositions and methods |
-
2019
- 2019-08-26 US US17/271,146 patent/US20210186870A1/en not_active Abandoned
- 2019-08-26 EP EP19854153.4A patent/EP3843763A4/en not_active Withdrawn
- 2019-08-26 WO PCT/IB2019/000964 patent/WO2020044118A1/en unknown
- 2019-08-26 CA CA3110447A patent/CA3110447A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017045053A1 (en) * | 2015-09-18 | 2017-03-23 | Prati, Donaduzzi & Cia Ltda | Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same |
Non-Patent Citations (2)
Title |
---|
"Evolab Unveils CBx Sciences Topical Product Line -- Unique Cannabis Formulations Featuring Rare Cannabinoids & Complementary Botanicals", PR NEWSWIRE, 1 November 2017 (2017-11-01), XP055695497, Retrieved from the Internet <URL:https://www.prnewswire.com/news-releases/evolab-unveils-cbx-sciences-topical-product-line--unique-cannabis-formulations-featuring-rare-cannabinoids--complementary-botanicals-300546833.html> [retrieved on 20191216] * |
See also references of EP3843763A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11478443B2 (en) | 2018-02-07 | 2022-10-25 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
US11701337B2 (en) | 2018-02-07 | 2023-07-18 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
US11712456B2 (en) | 2018-04-09 | 2023-08-01 | Portland Technology Holdings Llc | Hemp extract for treatment of pain in animals |
US11166933B2 (en) | 2018-05-03 | 2021-11-09 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
US11110372B2 (en) | 2018-08-08 | 2021-09-07 | Neptune Wellness Solutions Inc. | Cold extraction method for cannabinoids and terpenes from cannabis by organic solvents |
WO2021022378A1 (en) * | 2019-08-08 | 2021-02-11 | Neptune Wellness Solutions Inc. | Oral formulations of cannabis extracts and methods of making same |
WO2021041404A1 (en) * | 2019-08-26 | 2021-03-04 | Filipetto Gianna Marie | Method and apparatus for the infusion of cannabinoids into a shelf-stable food composition |
EP3987943A1 (en) * | 2020-10-21 | 2022-04-27 | Corn Products Development, Inc. | Cannabinoid emulsions |
WO2022122904A1 (en) * | 2020-12-09 | 2022-06-16 | Chanelle Mccoy Cbd Limited | A delayed-release capsule of cannabidiol |
IT202100014909A1 (en) | 2021-06-08 | 2022-12-08 | Velleja Res S R L | OILY FORMULATIONS OF CANNABINOIDS |
DE202022001128U1 (en) | 2022-05-09 | 2022-08-29 | Gabriele Blume | Nanoemulsions based on the emulsifier Imwitor 375 (glyceryl citrate/lactate/linoleate/oleate) and a coemulsifier to increase the bioavailability of poorly soluble, natural bioactive substances after oral intake. |
WO2024095090A1 (en) * | 2022-11-01 | 2024-05-10 | Aker Biomarine Antarctic As | Phospholipid compositions for delivery of therapeutic compounds |
Also Published As
Publication number | Publication date |
---|---|
CA3110447A1 (en) | 2020-03-05 |
EP3843763A4 (en) | 2022-06-15 |
US20210186870A1 (en) | 2021-06-24 |
EP3843763A1 (en) | 2021-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210186870A1 (en) | Improved cannabinoid bioavailability | |
CN111787910B (en) | Oral pharmaceutical formulation comprising cannabinoid and poloxamer | |
US11654111B2 (en) | Oral solid cannabinoid formulations, methods for producing and using thereof | |
US20230094827A1 (en) | Nanoemulsion compositions comprising biologically active ingredients | |
US20210267934A1 (en) | Cannabinoid oral dispersible film strip | |
KR20200106169A (en) | Modified release composition containing cannabinoids | |
CA3003120A1 (en) | Cannabinoid formulations | |
US20210236575A1 (en) | Therapeutic combinations of cannabinoids with curcumin | |
AU2022202308A1 (en) | Ubiquinone and ubiquinol compositions, and methods relating thereto | |
US20220288014A1 (en) | Oral formulations of cannabis extracts and methods of making same | |
WO2020044119A2 (en) | Oral formulations of lavender and cannabinoids | |
WO2021195173A1 (en) | Solid cannabinoid formulation for oral administration | |
EP3955898A1 (en) | Lozenge for improved delivery of cannabinoids | |
US20230030491A1 (en) | Emulsifying formulations of cannabinoids and/or cannabinoid extracts | |
US20210205236A1 (en) | Therapeutic combinations of boswellia extract and cannabinoids | |
US20230233466A1 (en) | Compositions for supplementing products with therapeutic agents and methods of use thereof | |
WO2020146478A1 (en) | Cannabinoid formulations for treating alcohol hangover | |
CA3119786A1 (en) | Cannabinoid compositions | |
CA3110778A1 (en) | Oral formulations of phenylalanine and cannabinoids | |
AU2017301077B2 (en) | Omega-3 compositions and methods relating thereto | |
RU2795027C2 (en) | Pharmaceutical drug | |
WO2023015378A1 (en) | Stabilization of cannabis resin and solid oral cannabinoid formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19854153 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3110447 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019854153 Country of ref document: EP Effective date: 20210329 |